WO2008086369A1 - Stents comportant des couches biodégradables - Google Patents
Stents comportant des couches biodégradables Download PDFInfo
- Publication number
- WO2008086369A1 WO2008086369A1 PCT/US2008/050536 US2008050536W WO2008086369A1 WO 2008086369 A1 WO2008086369 A1 WO 2008086369A1 US 2008050536 W US2008050536 W US 2008050536W WO 2008086369 A1 WO2008086369 A1 WO 2008086369A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- rapamycin
- polymer
- stent
- layers
- framework
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
- A61L31/08—Materials for coatings
- A61L31/10—Macromolecular materials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/82—Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/86—Stents in a form characterised by the wire-like elements; Stents in the form characterised by a net-like or mesh-like structure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
- A61L31/14—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
- A61L31/148—Materials at least partially resorbable by the body
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/82—Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/86—Stents in a form characterised by the wire-like elements; Stents in the form characterised by a net-like or mesh-like structure
- A61F2/90—Stents in a form characterised by the wire-like elements; Stents in the form characterised by a net-like or mesh-like structure characterised by a net-like or mesh-like structure
- A61F2/91—Stents in a form characterised by the wire-like elements; Stents in the form characterised by a net-like or mesh-like structure characterised by a net-like or mesh-like structure made from perforated sheet material or tubes, e.g. perforated by laser cuts or etched holes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2210/00—Particular material properties of prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof
- A61F2210/0004—Particular material properties of prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof bioabsorbable
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2210/00—Particular material properties of prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof
- A61F2210/0076—Particular material properties of prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof multilayered, e.g. laminated structures
Definitions
- the present invention relates to methods for forming stents comprising a bioabsorbable polymer and a pharmaceutical or biological agent in powder form onto a substrate.
- the invention provides a method of preparing a laminate coronary stent comprising: a. providing a stent framework; b. depositing a plurality of layers on said stent framework to form said laminate coronary stent; wherein at least one of said layers comprises a bioabsorbable polymer.
- the stent framework is bioabsorbable.
- the stent framework is made of absorbable material comprising magnesium.
- bioabsorbable polymer selected from PGA poly(glycolide), LPLA poly(l-lactide), DLPLA poly(dl-lactide), PCL poly(e-caprolactone) PDO, poly(dioxolanc) PGA-TMC, 85/15 DLPLG p(dl-lactide-co-glycolide), 75/25 DLPL, 65/35 DLPLG, 50/50 DLPLG, TMC poly(trimethylcarbonate), p(CPP:SA) poly(l,3-bis-p- (carboxyphenoxy)propane-co-sebacic acid).
- the one or more active agents comprise a rnacrolide immunosuppressive (limus) drug.
- the macrolide immunosuppressive drug comprises one or more of rapamycin, 40-O-(2-Hydroxyethyl)rapamycin (everolimus), 40-O- Benzyl-rapamycin, 40-O-(4'-Hydroxymethyl)benzyl-rapamycin, 40-O-[4'-(l ,2- Dihydroxyethyl)]benzyl-rapamycin, 40-O-Allyl-rapamycin, 40-O-[3'-(2,2-Dimethyl-l ,3- dioxolan-4(S)-y])- ⁇ rop-2'-en-l l -yl]-rapamycin ) (2':E,4 1 S)-40-O-(4',5 1 -Dihydroxypent-2'-en-r- yl)-rapamycin 40-O
- depositing a plurality of layers on said stent framework to form said laminate coronary stent comprises depositing polymer particles on said framework by an RESS process.
- the invention provides a laminate coronary stent comprising a. a stent framework; b. a plurality of layers deposited on said stent framework to form said laminate coronary stent; wherein at least one of said layers comprises a bioabsorbable polymer.
- a laminate coronary stent comprising: a. providing a stent framework; b.
- a supercritical or near supercritical fluid solution comprising at least one supercritical fluid solvent and at least one polymer and discharging said supercritical or near supercritical fluid solution through said first orifice or through a second orifice under conditions sufficient to form solid particles of the polymer; iii. depositing the polymer and pha ⁇ naccutical agent and/or active biological agent particles onto said framework, wherein an electrical potential is maintained between the framework and the polymer and pharmaceutical agent and/or active biological agent particles, thereby forming said layer; and iv. sintering said layer under conditions that do not substantially modify the morphology of said pharmaceutical agent and/or the activity of said biological agent.
- the framework is electrostatically charged.
- framework is biodegradable.
- FIG. 1 Yet another embodiment, provides a method of preparing coronary stent comprising: a. forming a sheet comprising a bioabsorbable polymer; b. carving out a pattern of said coronary stent into said sheet; and c. rolling said sheet to form said coronary stent.
- forming said sheet comprises depositing a plurality of layers to form said sheet and said coronary stent is a laminate coronary stent.
- Figures 1-10 illustrate various embodiments of the invention.
- the invention provides a process wherein a stent is constructed from the bottom-up.
- a stent-form (or framework) will be used as a template, onto which a laminated structure of bioabsorbable polymer(s) + dn ⁇ g(s) is overlaid - forming the final stent.
- This final stent may be fully bioabsorbable if an absorbable stent-form is utilized.
- a non-absorbable stent-form e.g. stainless steel
- all of the polymer and drug shall be absorbed/eluted, leaving only the very thin metallic stent-form embedded in the vessel wall.
- the stent-form can be an exact structural replica of the to-be- produced stent.
- the stent form would have approximately the same longitudinal and radial dimensions as the final stent.
- the stent form would have between 2x and 10Ox thinner wires/struts.
- the laminated structure provides significantly improved mechanical properties in a predominantly polymer-based, bioabsorbable, balloon-expandable stent.
- the laminated structure that results from successive coatings on the stent-form provides a mechanically effective stent (e.g. with deployed hoop strength > 300mm Hg luminal pressure) with thinner struts than traditional metallic stents and which are superior to the known bioabsorbable polymeric stents.
- the present methods apply several layers (2-100) of bioabsorbable polymer(s) to the stent form (coat-sinter-coat-sinter, repeat). This will result in a laminated polymer structure upon the stenl-form, thus building the struts up to the target dimensions for use (which may be smaller, the same or larger than a metallic stent of similar strut design - depending on the desired mechanical properties of the stent).
- Single or multiple drugs may be included in one, some or all of these layers. Alternatively the drugs could be located substantially between the polymer layers.
- This discreet location of drug/drugs is designed to provide specific, time-targeted elution profiles and may enable the elution of multiple drugs in serial fashion.
- Elements of this embodiment include: [0023] A. The stent form:
- the stent-form of the present invention is 2-10Ox thinner than a traditional stent (which makes it, in- and-of-itself, difficult to use without the added strength and physical properties of the polymer laminate(s)).
- B Means for creating the bioabsorbable polymer(s) + drug (s) matrix on the stent- form - forming the final device.
- the invention provides a process wherein the pattern of a stent is carved out of a sheet of polymeric material (e.g., a flat sheet).
- the polymeric sheet is a bioabsorbable polymer + drug(s) formulation.
- the sheet may contain a laminated structure of multiple layers (2-100) made from one or more bioabsorbable polymers.
- the sheet may contain none, one or multiple drugs.
- the laminated structure provides significantly improved mechanical properties in a predominantly polymer-based, bioabsorbable, balloon-expandable stent.
- the laminated structure that results from successive coatings on the stent-form may provide a mechanically effective stent (e.g. with deployed hoop strength > 300mm Hg luminal pressure) with thinner struts than traditional metallic stents and certainly superior to the known bioabsorbable polymeric stents.
- the Polymeric sheet material is ideally comprised of bioabsorbable polymers.
- the polymeric sheet material is ideally a laminated structure. In the laminate, we envision ideal properties to be obtained by alternating 'hard '-'soft' bioabsorbable polymers.
- the first material aspect of the invention is the creation and unique properties of the polymer film.
- the polymer sheet could be formed by a succession of coat-sinter-coat-sinter-coat-sinter steps.
- Inclusion of drug The drug can be formulated in one of three places within the polymer sheet.
- Carving of the stent architecture includes, without limitation: physical cutting by press, roller, knife, jet, or laser and/or chemically etched by wet- chemistry or dry-plasma means.
- One alternative method of carving may be to physically carve the stent architecture while the polymer sheet is exposed to a compressed fluid environment (e.g. similar to Micell's sintering process). Such exposure could 'soften' the polymer sheet aiding in carving.
- the invention provides improved mechanical properties compared to conventional bioabsorbable stents.
- the present invention provides a laminated bioabsorbable polymer stent, with significantly increased in strength, deformability, hoop stress (both pre- and post- expansion) and other mechanical properties.
- a laminate structure is inherently stronger and more effective in the deformation processes necessary for DES use (crimping onto a balloon, expansion into the diseased vessel).
- the invention provides the ability to obtain greater hoop-strength in the deployed stent based on the laminate architecture of the stents.
- the present invention allows the formation of a laminate of different bioabsorbable polymers (e.g., PLA, PGA and copolymers thereof) with different mechanical properties: hard-soft-hard-soft-hard-soft type of laminated structure.
- One attribute of a hard-soft structure will be to provide a unique and novel control of the pressure needed for expansion of the stent.
- the soft laminate layer By designing the soft laminate layer to act as the 'slip layer' or 'lubrication' between neighboring layers the stress needed for expansion can be 'dialed in' (range 3-30 atm pressure for full expansion).
- Another advantage of the present invention is the ability to create a stent with a completely novel drug-elution profile. Via the ability to have different materials in each layer of the laminate structure and the ability to control the location of drug(s) independently in these layers, the method enables a bioabsorbable stent that could release drugs at very specific elution profiles, programmed sequential and/or parallel elution profiles. Also, the present invention allows controlled elution of one drug without affecting the elution of a second drug (or different doses of the same drug).
- the embodiments incorporating a stent form or framework provide the ability to radiographically monitor the stent in deployment.
- the inner- diameter of the stent can be masked (e.g. by a non-conductive mandrel). Such masking would prevent additional layers from being on the interior diameter (abluminal) surface of the stent.
- the resulting configuration may be desirable to provide preferential elution of the drug toward the vessel wall (luminal surface of the stent) where the therapeutic effect of anti- restenosis is desired, without providing the same antiproliferative drug(s) on the abluminal surface, where they may retard healing, which in turn is suspected to be a cause of late-stage safety problems with current DESs.
- the present invention provides numerous advantages.
- the invention is advantageous allows for employing a platform combining layer formation methods based on compressed fluid technologies; electrostatic capture and sintering methods.
- the platform results in drug eluting stents having enhanced therapeutic and mechanical properties.
- the invention is particularly advantageous in that it employs optimized laminate polymer technology.
- the present invention allows the fo ⁇ nation of discrete layers of specific drug platforms.
- Conventional processes for spray coating stents require that drug and polymer be dissolved in solvent or mutual solvent before spray coating can occur.
- the platform provided herein the drugs and polymers are coated on the stent framework in discrete steps, which can be carried out simultaneously or alternately.
- the present platform provides a dual drug eluting stent.
- Some of the advantages provided by the subject invention include employing compressed fluids (e.g., supercritical fluids, for example E-RESS based methods); solvent free deposition methodology; a platform that allows processing at lower temperatures thereby preserving the qualities of the active agent and the polymer matrix; the ability to incorporate two, three or more drugs while minimizing deleterious effects from direct interactions between the various drugs and/or their excipients during the fabrication and/or storage of the drug eluting stents; a dry deposition; enhanced adhesion and mechanical properties of the layers on the stent framework; precision deposition and rapid batch processing; and ability to form intricate structure.
- compressed fluids e.g., supercritical fluids, for example E-RESS based methods
- solvent free deposition methodology e.g., solvent free deposition methodology
- the present invention provides a multi-drug delivery platform which produces strong, resilient and flexible drug eluting stents including an anti-restenosis drug (e.g.; a litnus or taxol) and anti-thrombosis drug (e.g.; heparin or an analog thereof) and well characterized bioabsorbable polymers.
- the drug eluting stents provided herein minimize potential for thrombosis, in part, by reducing or totally eliminating thrombogenic polymers and reducing or totally eliminating residual drugs that could inhibit healing.
- the platform provides optimized delivery of multiple drug therapies for example for early stage treatment (restenosis) and late-stage (thrombosis).
- the platform also provides an adherent coating which enables access through tortuous lesions without the risk of the coating being compromised.
- Another advantage of the present platform is the ability to provide highly desirable eluting profiles (e.g., the profile illustrated in Figures 1-10).
- Advantages of the invention include the ability to reduce or completely eliminate potentially thrombogenic polymers as well as possibly residual drugs that may inhibit long term healing.
- the invention provides advantageous stents having optimized strength and resilience if coatings which in turn allows access to complex lesions and reduces or completely eliminates delamination. Laminated layers of bioabsorbable polymers allow controlled elution of one or more drugs.
- the platform provided herein reduces or completely eliminates shortcoming that have been associated with conventional drug eluting stents.
- the platform provided herein allows for much better tuning of the period of time for the active agent to elute and the period of time necessary for the polymer matrix to resorb thereby minimizing thrombosis and other deleterious effects associate with poorly controlled drug release. [0052] Additional advantages of the present platform are illustrated in Figures 1-10. Definitions
- Substrate refers to any surface upon which it is desirable to deposit a coating comprising a polymer and a pharmaceutical or biological agent, wherein the coating process docs not substantially modify the morphology of the pharmaceutical agent or the activity of the biological agent.
- Biomedical implants are of particular interest for the present invention; however the present invention is not intended to be restricted to this class of substrates.
- substrates that could benefit from the coating process described herein, such as pharmaceutical tablet cores, as part of an assay apparatus or as components in a diagnostic kit (e.g. a test strip).
- Biomedical implant refers to any implant for insertion into the body of a human or animal subject, including but not limited to stents (e.g., vascular stents), electrodes, catheters, leads, implantable pacemaker, cardioverter or defibrillator housings, joints, screws, rods, ophthalmic implants, femoral pins, bone plates, grafts, anastomotic devices, perivascular wraps, sutures, staples, shunts for hydrocephalus, dialysis grafts, colostomy bag attachment devices, ear drainage tubes, leads for pace makers and implantable cardioverters and defibrillators, vertebral disks, bone pins, suture anchors, hemostatic barriers, clamps, screws, plates, clips, vascular implants, tissue adhesives and sealants, tissue scaffolds, various types of dressings (e.g., wound dressings), bone substitutes, intraluminal devices, vascular supports, etc.
- stents e.g.,
- the implants may be formed from any suitable material, including but not limited to organic polymers (including stable or inert polymers and biodegradable polymers), metals, inorganic materials such as silicon, and composites thereof, including layered structures with a core of one material and one or more coatings of a different material.
- Substrates made of a conducting material facilitate electrostatic capture.
- the invention contemplates the use of electrostatic capture in conjunction with substrate having low conductivity or which non-conductive. To enhance electrostatic capture when a non-conductive substrate is employed, the substrate is processed while maintaining a strong electrical field in the vicinity of the substrate.
- biomedical implants of the invention include both human subjects (including male and female subjects and infant, juvenile, adolescent, adult and geriatric subjects) as well as animal subjects (including but not limited to dog, cat, horse, monkey, etc.) for veterinary purposes.
- the biomedical implant is an expandable intraluminal vascular graft or stent (e.g., comprising a wire mesh tube) that can be expanded within a blood vessel by an angioplasty balloon associated with a catheter to dilate and expand the lumen of a blood vessel, such as described in US Patent No. 4,733,665 to Palmaz Shaz.
- "Pharmaceutical agent” as used herein refers to any of a variety of drugs or pharmaceutical compounds that can be used as active agents to prevent or treat a disease (meaning any treatment of a disease in a mammal, including preventing the disease, i.e. causing the clinical symptoms of the disease not to develop; inhibiting the disease, i.e.
- the pharmaceutical agents of the invention may also comprise two or more drugs or pharmaceutical compounds.
- Pharmaceutical agents include but are not limited to antirestenotic agents, antidiabetics, analgesics, antiinflammatory agents, antirheumatics, antihypotensive agents, antihypertensive agents, psychoactive drugs, tranquillizers, antiemetics, muscle relaxants, glucocorticoids, agents for treating ulcerative colitis or Crohn's disease, antiallergics, antibiotics, antiepileptics, anticoagulants, antimycotics, antitussives, arteriosclerosis remedies, diuretics, proteins, peptides, enzymes, enzyme inhibitors, gout remedies, hormones and inhibitors thereof, cardiac glycosides, immunotherapeutic agents and cytokines, laxatives, lipid- lowering agents, migraine remedies, mineral products, otologicals, anti parkinson agents, thyroid therapeutic agents, antirheumatics, antihypotensive agents, antihypertensive agents, psychoactive drugs, tranquilliz
- Suitable active ingredients are acarbosc, antigens, beta-receptor blockers, nonsteroidal antiinflammatory drugs (NSAIDs], cardiac glycosides, acetylsalicylic acid, virustatics, aclarubicin, acyclovir, cisplatin, actinomycin, alpha- and beta-sympatomimetics, (dmeprazole, allopurinol, alprostadil, prostaglandins, amantadine, ambroxol, amlodipine, methotrexate, S-aminosalicylic acid, amitriptyline, amoxicillin, anastrozole, atenolol, azathioprine, balsalazide, beclomcthasone, betahistine, bezafibrate, bicalutamide, diazepam and diazepam derivatives, budesonide, bufexamac, buprcnorphine,
- Examples of therapeutic agents employed in conjunction with the invention include, rapamycin, 40-O-(2-Hydroxyethyl)rapamycin (everolimus), 40-O-Benzyl-rapamycin, 40-O- (4'-Hydroxymethyl)benzyl-rapamycin, 40-O-[4'-(l ,2-Dihydroxycthyl)]benzyl-rapamycin, 40- O-AUyl-rapamycin, 40-O-[3'-(2,2-Dimethyl-l,3-dioxolan-4(S)-yl)-prop-2'-en-l'-yl]- rapamycin, (2':E,4 t S)-40-O-(4',5'-Dihydroxypent-2'-en- 1 '-yl)-rapamycin 40-O-(2-Hydroxyethyl)rapamycin (everolimus), 40-O-Benzyl-rapamycin, 40-O- (4'-
- TolylsulfonamidoethyO-rapamycin 40-O-[2-(4',5'-Dicarboethoxy-r,2',3'-triazol-r-yl)-ethyl]- rapamycin, 42-Epi-(tetrazolyl)rapamycin (tacrolimus), and 42-[3-hydroxy-2- (hydroxymethyl)-2-methylpropanoate]rapamycin (temsirolimus).
- acti ⁇ 'e ingredients may, if desired, also be used in the form of their pharmaceutically acceptable salts or derivatives (meaning salts which retain the biological effectiveness and properties of the compounds of this invention and which are not biologically or otherwise undesirable), and in the case of chiral active ingredients it is possible to employ both optically active isomers and racemates or mixtures of diastereoisomers.
- Stability refers to the stability of the drug in a polymer coating deposited on a substrate in its final product form (e.g., stability of the drug in a coated stent). The term stability will define 5% or less degradation of the drug in the final product form.
- 00631 Active biological agent as used herein refers to a substance, originally produced by living organisms, that can be used to prevent or treat a disease (meaning any treatment of a disease in a mammal, including preventing the disease, i.e. causing the clinical symptoms of the disease not to develop; inhibiting the disease, i.e. arresting the development of clinical symptoms; and/or relieving the disease, i.e. causing the regression of clinical symptoms).
- the active biological agents of the invention may also comprise two or more active biological agents or an active biological agent combined with a pharmaceutical agent, a stabilizing agent or chemical or biological entity.
- the active biological agent may have been originally produced by living organisms, those of the present invention may also have been synthetically prepared, or by methods combining biological isolation and synthetic modification.
- a nucleic acid could be isolated form from a biological source, or prepared by traditional techniques, known to those skilled in the art of nucleic acid synthesis.
- the nucleic acid may be further modified to contain non- naturally occurring moieties.
- Non-limiting examples of active biological agents include peptides, proteins, enzymes, glycoproteins, nucleic acids (including deoxyribonucleotide or ribonucleotide polymers in either single or double stranded form, and unless otherwise limited, encompasses known analogues of natural nucleotides that hybridize to nucleic acids in a manner similar to naturally occurring nucleotides), antisense nucleic acids, fatty acids, antimicrobials, vitamins, hormones, steroids, lipids, polysaccharides, carbohydrates and the like.
- antirestenotic agents antidiabetics, analgesics, antiinflammatory agents, antirheumatics, antihypotensive agents, antihypertensive agents, psychoactive drugs, tranquillizers, antiemetics, muscle relaxants, glucocorticoids, agents for treating ulcerative colitis or Crohn's disease, antiallergics, antibiotics, antiepileptics, anticoagulants, antimycotics, antitussives, arteriosclerosis remedies, diuretics, proteins, peptides, enzymes, enzyme inhibitors, gout remedies, hormones and inhibitors thereof, cardiac glycosides, immunotherapeutic agents and cytokines, laxatives, lipid- lowering agents, migraine remedies, mineral products, otologicals, anti parkinson agents, thyroid therapeutic agents, spasmolytics, platelet aggregation inhibitors, vitamins, cytostatics and metastasis inhibitors, phytopharmaceuticals and chemotherapeutic agents.
- analgesics antiinflammatory agents, antirhe
- Activity refers to the ability of a pharmaceutical or active biological agent to prevent or treat a disease (meaning any treatment of a disease in a mammal, including preventing the disease, i.e. causing the clinical symptoms of the disease not to develop; inhibiting the disease, i.e. arresting the development of clinical symptoms; and/or relieving the disease, i.e. causing the regression of clinical symptoms).
- a pharmaceutical or active biological agent should be of therapeutic or prophylactic value.
- the active biological agents of the present invention will typically possess some degree of secondary, tertiary and/or quaternary structure, upon which the activity of the agent depends.
- proteins possess secondary, tertiary and quaternary structure.
- Secondary structure refers to the spatial arrangement of amino acid residues that are near one another in the linear sequence.
- the ⁇ -helix and the /S-strand are elements of secondary structure.
- Tertiary structure refers to the spatial arrangement of amino acid residues that are far apart in the linear sequence and to the pattern of disulfide bonds.
- Proteins containing more than one polypeptide chain exhibit an additional level of structural organization. Each polypeptide chain in such a protein is called a subunit.
- Quaternary structure refers to the spatial arrangement of subunits and the nature of their contacts.
- hemoglobin consists of two a and two ⁇ chains. It is well known that protein function arises from its conformation or three dimensional arrangement of atoms (a stretched out polypeptide chain is devoid of activity).
- one aspect of the present invention is to manipulate active biological agents, while being careful to maintain their conformation, so as not to lose their therapeutic activity.
- Polymer refers to a series of repeating monomeric units that have been cross-linked or polymerized. Any suitable polymer can be used to carry out the present invention. It is possible that the polymers of the invention may also comprise two, three, four or more different polymers.
- polymers In some embodiments, of the invention only one polymer is used. In some preferred embodiments a combination of two polymers are used. Combinations of polymers can be in varying ratios, to provide coatings with differing properties. Those of skill in the art of polymer chemistry will be familiar with the different properties of polymeric compounds.
- Therapeutically desirable morphology refers to the gross form and structure of the pharmaceutical agent, once deposited on the substrate, so as to provide for optimal conditions of ex vivo storage, in vivo preservation and/or in vivo release. Such optimal conditions may include, but arc not limited to increased shelf life, increased in vivo stability, good biocompatibility, good bioavailability or modified release rates.
- the desired morphology of a pharmaceutical agent would be crystalline or semi-crystalline or amorphous, although this may vary widely depending on many factors including, but not limited to, the nature of the pharmaceutical agent, the disease to be treated/prevented, the intended storage conditions for the substrate prior to use or the location within the body of any biomedical implant. Preferably at least 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90% or 100% of the pharmaceutical agent is in crystalline or semi- crystalline form.
- Stabilizing agent refers to any substance that maintains or enhances the stability of the biological agent.
- stabilizing agents are classified as Generally Regarded As Safe (GRAS) materials by the US Food and Drug Administration (FDA).
- stabilizing agents include, but are not limited to carrier proteins, such as albumin, gelatin, metals or inorganic salts.
- Pharmaceutically acceptable excipient that may be present can further be found in the relevant literature, for example in the Handbook of Pharmaceutical Additives: An International Guide to More Than 6000 Products by Trade Name, Chemical, Function, and Manufacturer; Michael and Irene Ash (Eds.); Gower Publishing Ltd.; Aldershot, Hampshire, England, 1995. [0069J "Compressed fluid” as used herein refers to a fluid of appreciable density (e.g., >0.2 g/cc) that is a gas at standard temperature and pressure.
- Supercritical fluid refers to a compressed fluid under conditions wherein the temperature is at lease 80% of the critical temperature of the fluid and the pressure is at least 50% of the critical pressure of the Quid.
- Examples of substances that demonstrate supercritical or near critical behavior suitable for the present invention include, but are not limited to carbon dioxide, isobutylcne, ammonia, water, methanol, ethanol, ethane, propane, butane, pentane, dimethyl ether, xenon, sulfur hexafluoride, halogenatcd and partially halogenated materials such as chlorofluorocarbons, hydrochlorofluorocarbons, hydrofluorocarbons, perfluorocarbons (such as perfluoromethane and perfuoropropane, chlorofo ⁇ n, trichloro-fluoromethane, dichloro- difluoromethane, dichloro-tetrafluoroethane) and mixtures thereof.
- “Sintering” as used herein refers to the process by which parts of the matrix or the entire polymer matrix becomes continuous (e.g., formation of a continuous polymer film). As discussed below, the sintering process is controlled to produce a fully conformal continuous matrix (complete sintering) or to produce regions or domains of continuous coating while producing voids (discontinuities) in the matrix. As well, the sintering process is controlled such that some phase separation is obtained between polymer different polymers (e.g., polymers A and B) and/or to produce phase separation between discrete polymer particles. Through the sintering process, the adhesions properties of the coating are improved to reduce flaking of detachment of the coating from the substrate during manipulation in use.
- the sintering process is controlled to provide incomplete sintering of the polymer matrix.
- a polymer matrix is formed with continuous domains, and voids, gaps, cavities, pores, channels or, interstices that provide space for sequestering a therapeutic agent which is released under controlled conditions.
- a compressed gas, a densified gas, a near critical fluid or a super-critical fluid may be employed.
- carbon dioxide is used to treat a substrate that has been coated with a polymer and a drug, using dry powder and RESS electrostatic coating processes.
- isobutylene is employed in the sintering process. In other examples a mixture of carbon dioxide and isobutylene is employed.
- reaction that is minimized by the processes of the invention relates to the ability to avoid conventional solvents which in rum minimizes autoxidation of drug, whether in amorphous, semi-crystalline, or crystalline form, by reducing exposure thereof to free radicals, residual solvents and autoxidation initiators.
- "Rapid Expansion of Supercritical Solutions” or “RESS” as used herein involves the dissolution of a polymer into a compressed fluid, typically a supercritical fluid, followed by rapid expansion into a chamber at lower pressure, typically near atmospheric conditions. The rapid expansion of the supercritical fluid solution through a small opening, with its accompanying decrease in density, reduces the dissolution capacity of the fluid and results in the nucleation and growth of polymer particles.
- the atmosphere of the chamber is maintained in an electrically neutral state by maintaining an isolating "cloud" of gas in the chamber. Carbon dioxide or other appropriate gas is employed to prevent electrical charge is transferred from the substrate to the surrounding environment.
- “Bulk properties" properties of a coating including a pharmaceutical or a biological agent that can be enhanced through the methods of the invention include for example: adhesion, smoothness, con formality, thickness, and compositional mixing.
- “Electrostatically charged” or “electrical potential” or “electrostatic capture” as used herein refers to the collection of the spray-produced particles upon a substrate that has a different electrostatic potential than the sprayed particles.
- the substrate is at an attractive electronic potential with respect to the particles exiting, which results in the capture of the particles upon the substrate, i.e. the substrate and particles are oppositely charged, and the particles transport through the fluid medium of the capture vessel onto the surface of the substrate is enhanced via electrostatic attraction.
- the present invention provides several advantages which overcome or attenuate the limitations of current technology for bioabsorbable stents.
- an inherent limitation of conventional bioabsorbable polymeric materials relates to the difficulty in forming to a strong, flexible, deformablc (e.g. balloon deployable) stent with low profile.
- the polymers generally lack the strength of high-performance metals.
- the present invention overcomes these limitations by creating a laminate structure in the essentially polymeric stent.
- the increased strength provided by the stents of the invention canbe understood by comparing the strength of plywood vs. the strength of a thin sheet of wood.
- Embodiments of the invention involving a thin metallic stent-framework provide advantages including the ability to overcome the inherent elasticity of most polymers. It is generally difficult to obtain a high rate (e.g., 100%) of plastic deformation in polymers (compared to elastic deformation where the materials have some 'spring back' to the original shape).
- a sheet of polymer film is imprinted by rolling a cylinder across the surface of the sheet.
- the polymer sheet is made from bioabsorbable polymers prepared by spraying alternating layers of different polymers onto a conductive substrate. The order in which the layers are applied is determined by the desired film mechanical properties. Drug may be applied between each layer or selectively between desired layers. Drug is applied using a dry powder coating technique.
- a cylindrical, patterned rod is rolled across the polymer film creating a stent in a gravure printing like process.
- Several methods exist for creating the pattered rod such as using photoresist-etch process. Alternatively the pattern could be laser cut into the solid rod.
- the flat polymer sheet is cut into strips with widths slightly greater than the circumference of the finished stent.
- the polymer strips are then rolled around a lubricious non-patterned cylinder (i.e., Teflon) that acts as a form.
- This object is then placed in pressure vessel and sealed.
- Gas such as dichlorofluoromethanc is added to the pressure vessel until the pressure inside the vessel equals the vapor pressure of the gas at the temperature of the vessel.
- a suitable gas is dichlorofluoromethane at a temperature of 37 0 C.
- the gas sinters the polymer strip and welds the seam together creating a polymeric stent supported on a Teflon cylinder. After the stent is sintered it is slid off the support.
- Example 2
- a bioabsorable metal such as magnesium is used as a form onto which bioabsorbable polymer(s) can be sprayed in layered fashion.
- a polymer layer of one type such as PLA is sprayed on the stent and sintered.
- a second polymer layer of another type such as PGA is then sprayed onto the metal form holding the first polymer layer.
- the stent is sintered again to create a tri-layered structure consisting of metal-polymer type I-polymer type II. The process could be repeated with the same or additional types of polymers to build a coating of desired thickness and desired mechanical properties.
- drug such as rapamycin or Taxol or other anti-restenotic could be dry powder coated onto any given polymer layer or the metal base stent itself.
- a metal, such as stainless steel, base stent is etched to a vanishingly small size while being supported on a Teflon or similarly lubricious rod.
- the outside diameter of the rod is slightly smaller than the inside diameter of the stent and serves to support the etched metal stent and mask the inside (luminal) surface.
- the mask should limit the amount of material deposited on this surface.
- the stent can coated as in example 2 to achieve the desired mechanical and coating properties.
- a second drug can be deposited in any desired layer to achieve a desired elution profile.
- An alternative to example 3 is removal of the mask for the luminal surface of the stent. Both the stent surfaces are coated with drug(s) and polymer. The stent is supported by its own mechanical strength on the stent fixture.
- a single or multiple drugs (Paclitaxel or Picrolimus, for example) can be deposited in any layer of the polymer coating or through the thickness of the polymer coat
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Heart & Thoracic Surgery (AREA)
- Vascular Medicine (AREA)
- Epidemiology (AREA)
- Surgery (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Cardiology (AREA)
- Transplantation (AREA)
- Oral & Maxillofacial Surgery (AREA)
- Materials For Medical Uses (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Media Introduction/Drainage Providing Device (AREA)
Abstract
Priority Applications (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN200880007308.1A CN101711137B (zh) | 2007-01-08 | 2008-01-08 | 具有可生物降解层的支架 |
CA2679712A CA2679712C (fr) | 2007-01-08 | 2008-01-08 | Stents comportant des couches biodegradables |
JP2009545647A JP5603598B2 (ja) | 2007-01-08 | 2008-01-08 | 生物分解層を有するステント |
US12/522,379 US9737642B2 (en) | 2007-01-08 | 2008-01-08 | Stents having biodegradable layers |
EP08705772.5A EP2111184B1 (fr) | 2007-01-08 | 2008-01-08 | Stents comportant des couches biodégradables |
US15/634,246 US10617795B2 (en) | 2007-01-08 | 2017-06-27 | Stents having biodegradable layers |
US16/784,842 US11426494B2 (en) | 2007-01-08 | 2020-02-07 | Stents having biodegradable layers |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US88400507P | 2007-01-08 | 2007-01-08 | |
US60/884,005 | 2007-01-08 | ||
US91240807P | 2007-04-17 | 2007-04-17 | |
US60/912,408 | 2007-04-17 |
Related Child Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US12/522,379 A-371-Of-International US9737642B2 (en) | 2007-01-08 | 2008-01-08 | Stents having biodegradable layers |
US15/634,246 Continuation US10617795B2 (en) | 2007-01-08 | 2017-06-27 | Stents having biodegradable layers |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2008086369A1 true WO2008086369A1 (fr) | 2008-07-17 |
Family
ID=39609056
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2008/050536 WO2008086369A1 (fr) | 2007-01-08 | 2008-01-08 | Stents comportant des couches biodégradables |
Country Status (6)
Country | Link |
---|---|
US (2) | US9737642B2 (fr) |
EP (1) | EP2111184B1 (fr) |
JP (2) | JP5603598B2 (fr) |
CN (1) | CN101711137B (fr) |
CA (1) | CA2679712C (fr) |
WO (1) | WO2008086369A1 (fr) |
Cited By (27)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2011130448A1 (fr) * | 2010-04-16 | 2011-10-20 | Micell Technologies, Inc. | Endoprothèses vasculaires ayant une élution contrôlée |
WO2011136882A1 (fr) * | 2010-04-29 | 2011-11-03 | Medtronic Vascular Inc. | Système et procédé de fabrication d'une endoprothèse |
US8758429B2 (en) | 2005-07-15 | 2014-06-24 | Micell Technologies, Inc. | Polymer coatings containing drug powder of controlled morphology |
US8795762B2 (en) | 2010-03-26 | 2014-08-05 | Battelle Memorial Institute | System and method for enhanced electrostatic deposition and surface coatings |
US8834913B2 (en) | 2008-12-26 | 2014-09-16 | Battelle Memorial Institute | Medical implants and methods of making medical implants |
US8852625B2 (en) | 2006-04-26 | 2014-10-07 | Micell Technologies, Inc. | Coatings containing multiple drugs |
US8900651B2 (en) | 2007-05-25 | 2014-12-02 | Micell Technologies, Inc. | Polymer films for medical device coating |
US9433516B2 (en) | 2007-04-17 | 2016-09-06 | Micell Technologies, Inc. | Stents having controlled elution |
US9486431B2 (en) | 2008-07-17 | 2016-11-08 | Micell Technologies, Inc. | Drug delivery medical device |
US9510856B2 (en) | 2008-07-17 | 2016-12-06 | Micell Technologies, Inc. | Drug delivery medical device |
US9539593B2 (en) | 2006-10-23 | 2017-01-10 | Micell Technologies, Inc. | Holder for electrically charging a substrate during coating |
US9636309B2 (en) | 2010-09-09 | 2017-05-02 | Micell Technologies, Inc. | Macrolide dosage forms |
US9737642B2 (en) | 2007-01-08 | 2017-08-22 | Micell Technologies, Inc. | Stents having biodegradable layers |
US9789233B2 (en) | 2008-04-17 | 2017-10-17 | Micell Technologies, Inc. | Stents having bioabsorbable layers |
US9981072B2 (en) | 2009-04-01 | 2018-05-29 | Micell Technologies, Inc. | Coated stents |
WO2018145528A1 (fr) * | 2017-02-13 | 2018-08-16 | 先健科技(深圳)有限公司 | Instrument médical |
US10117972B2 (en) | 2011-07-15 | 2018-11-06 | Micell Technologies, Inc. | Drug delivery medical device |
US10188772B2 (en) | 2011-10-18 | 2019-01-29 | Micell Technologies, Inc. | Drug delivery medical device |
US10232092B2 (en) | 2010-04-22 | 2019-03-19 | Micell Technologies, Inc. | Stents and other devices having extracellular matrix coating |
US10272606B2 (en) | 2013-05-15 | 2019-04-30 | Micell Technologies, Inc. | Bioabsorbable biomedical implants |
US10464100B2 (en) | 2011-05-31 | 2019-11-05 | Micell Technologies, Inc. | System and process for formation of a time-released, drug-eluting transferable coating |
US10835396B2 (en) | 2005-07-15 | 2020-11-17 | Micell Technologies, Inc. | Stent with polymer coating containing amorphous rapamycin |
US11039943B2 (en) | 2013-03-12 | 2021-06-22 | Micell Technologies, Inc. | Bioabsorbable biomedical implants |
EP3868434A1 (fr) | 2016-02-08 | 2021-08-25 | Orbusneich Medical Pte. Ltd | Ballonnet à élution de médicament |
US11369498B2 (en) | 2010-02-02 | 2022-06-28 | MT Acquisition Holdings LLC | Stent and stent delivery system with improved deliverability |
US11426494B2 (en) | 2007-01-08 | 2022-08-30 | MT Acquisition Holdings LLC | Stents having biodegradable layers |
US11904118B2 (en) | 2010-07-16 | 2024-02-20 | Micell Medtech Inc. | Drug delivery medical device |
Families Citing this family (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20070009564A1 (en) * | 2005-06-22 | 2007-01-11 | Mcclain James B | Drug/polymer composite materials and methods of making the same |
AU2008242844A1 (en) * | 2007-04-17 | 2008-10-30 | Micell Technologies, Inc. | Stents having biodegradable layers |
DE202008018589U1 (de) | 2007-09-26 | 2016-03-14 | St. Jude Medical, Inc. | Zusammenfaltbare Herzklappenprothesen |
US20100298928A1 (en) * | 2007-10-19 | 2010-11-25 | Micell Technologies, Inc. | Drug Coated Stents |
EP2410954A4 (fr) * | 2009-03-23 | 2014-03-05 | Micell Technologies Inc | Endoprothèses périphériques dotées de couches |
CN102824236B (zh) * | 2011-06-16 | 2016-01-20 | 乐普(北京)医疗器械股份有限公司 | 一种生物可吸收聚合物支架基体及其制备方法和应用 |
EP2768571B1 (fr) * | 2011-10-18 | 2023-02-22 | Micell Technologies, Inc. | Dispositif médical d'administration de médicament |
WO2013176769A1 (fr) * | 2012-05-21 | 2013-11-28 | University Of Cincinnati | Procédés de fabrication d'endoprothèses biodégradables à base de magnésium pour des applications d'implant médical |
JP6535282B2 (ja) * | 2014-04-24 | 2019-06-26 | 学校法人東海大学 | 高分子積層体 |
CN104983492A (zh) * | 2015-08-14 | 2015-10-21 | 上海百心安生物技术有限公司 | 一种辅助可吸收支架进行药物喷涂的喷涂内衬结构及方法 |
US10201639B2 (en) * | 2017-05-01 | 2019-02-12 | 480 Biomedical, Inc. | Drug-eluting medical implants |
CN107095728A (zh) * | 2017-05-19 | 2017-08-29 | 东莞颠覆产品设计有限公司 | 管腔内载药支架 |
US11998654B2 (en) | 2018-07-12 | 2024-06-04 | Bard Shannon Limited | Securing implants and medical devices |
Citations (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4733665A (en) | 1985-11-07 | 1988-03-29 | Expandable Grafts Partnership | Expandable intraluminal graft, and method and apparatus for implanting an expandable intraluminal graft |
US20020091433A1 (en) * | 1995-04-19 | 2002-07-11 | Ni Ding | Drug release coated stent |
US6497729B1 (en) | 1998-11-20 | 2002-12-24 | The University Of Connecticut | Implant coating for control of tissue/implant interactions |
US20030204238A1 (en) * | 2002-04-26 | 2003-10-30 | Eugene Tedeschi | Coated stent with crimpable coating |
US20030222017A1 (en) | 2002-05-28 | 2003-12-04 | Battelle Memorial Institute | Electrostatic deposition of particles generated from rapid expansion of supercritical fluid solutions |
US20040106982A1 (en) * | 1999-03-16 | 2004-06-03 | Jalisi Marc M. | Multilayer stent |
US20040193262A1 (en) * | 2003-03-29 | 2004-09-30 | Shadduck John H. | Implants for treating ocular hypertension, methods of use and methods of fabrication |
US6838528B2 (en) | 2001-01-19 | 2005-01-04 | Nektar Therapeutics Al, Corporation | Multi-arm block copolymers as drug delivery vehicles |
US20050010275A1 (en) * | 2002-10-11 | 2005-01-13 | Sahatjian Ronald A. | Implantable medical devices |
US20050049694A1 (en) * | 2003-08-07 | 2005-03-03 | Medtronic Ave. | Extrusion process for coating stents |
US20050069630A1 (en) * | 2003-09-30 | 2005-03-31 | Advanced Cardiovascular Systems, Inc. | Stent mandrel fixture and method for selectively coating surfaces of a stent |
US6897205B2 (en) | 2001-01-31 | 2005-05-24 | Roehm Gmbh & Co. Kg | Multi-particulate form of medicament, comprising at least two differently coated forms of pellet |
US20050177223A1 (en) * | 2003-09-18 | 2005-08-11 | Palmaz Julio C. | Medical devices having MEMs functionality and methods of making same |
US20060020325A1 (en) * | 2004-07-26 | 2006-01-26 | Robert Burgermeister | Material for high strength, controlled recoil stent |
US20060136041A1 (en) * | 2004-12-17 | 2006-06-22 | Schmid Eric V | Slide-and-lock stent |
US20060134211A1 (en) * | 2004-12-16 | 2006-06-22 | Miv Therapeutics Inc. | Multi-layer drug delivery device and method of manufacturing same |
US20060193890A1 (en) * | 2002-11-13 | 2006-08-31 | Owens Gary K | Method for loading nanoporous layers with therapeutic agent |
Family Cites Families (581)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3123077A (en) * | 1964-03-03 | Surgical suture | ||
US3087860A (en) | 1958-12-19 | 1963-04-30 | Abbott Lab | Method of prolonging release of drug from a precompressed solid carrier |
US3087660A (en) * | 1962-07-24 | 1963-04-30 | Yankee Plasties Inc | Two-step garment hanger |
US3457280A (en) | 1967-06-12 | 1969-07-22 | American Cyanamid Co | Alpha-glycolide and methods for the isolation thereof |
US3597449A (en) | 1967-11-16 | 1971-08-03 | American Cyanamid Co | Stable glycolide and lactide composition |
US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
DE2010115A1 (de) | 1970-03-04 | 1971-09-16 | Farbenfabriken Bayer Ag, 5090 Leverkusen | Verfahren zur Herstellung von Mikrogranulaten |
ZA737247B (en) | 1972-09-29 | 1975-04-30 | Ayerst Mckenna & Harrison | Rapamycin and process of preparation |
US4000137A (en) | 1975-06-10 | 1976-12-28 | American Home Products Corporation | Antitumor derivatives of periodate-oxidized nucleosides |
US4188373A (en) | 1976-02-26 | 1980-02-12 | Cooper Laboratories, Inc. | Clear, water-miscible, liquid pharmaceutical vehicles and compositions which gel at body temperature for drug delivery to mucous membranes |
US4285987A (en) | 1978-10-23 | 1981-08-25 | Alza Corporation | Process for manufacturing device with dispersion zone |
JPS5668674A (en) | 1979-11-08 | 1981-06-09 | Shionogi & Co Ltd | 5-fluorouracil derivative |
US4326532A (en) * | 1980-10-06 | 1982-04-27 | Minnesota Mining And Manufacturing Company | Antithrombogenic articles |
US4389330A (en) | 1980-10-06 | 1983-06-21 | Stolle Research And Development Corporation | Microencapsulation process |
US4675189A (en) | 1980-11-18 | 1987-06-23 | Syntex (U.S.A.) Inc. | Microencapsulation of water soluble active polypeptides |
US4474572A (en) | 1981-09-29 | 1984-10-02 | Syntex (U.S.A.) Inc. | Implanting device and implant magazine |
SE445884B (sv) * | 1982-04-30 | 1986-07-28 | Medinvent Sa | Anordning for implantation av en rorformig protes |
US4530840A (en) | 1982-07-29 | 1985-07-23 | The Stolle Research And Development Corporation | Injectable, long-acting microparticle formulation for the delivery of anti-inflammatory agents |
SE435444B (sv) | 1983-02-25 | 1984-10-01 | Hakan Johansson | Fiskeredskap med en fangstlina som utgores av en ljusledare |
US4606347A (en) | 1983-03-25 | 1986-08-19 | Thomas J. Fogarty | Inverted balloon catheter having sealed through lumen |
US4478822A (en) | 1983-05-16 | 1984-10-23 | Merck & Co., Inc. | Drug delivery system utilizing thermosetting gels |
US4474751A (en) | 1983-05-16 | 1984-10-02 | Merck & Co., Inc. | Ophthalmic drug delivery system utilizing thermosetting gels |
US4734227A (en) * | 1983-09-01 | 1988-03-29 | Battelle Memorial Institute | Method of making supercritical fluid molecular spray films, powder and fibers |
US4582731A (en) * | 1983-09-01 | 1986-04-15 | Battelle Memorial Institute | Supercritical fluid molecular spray film deposition and powder formation |
US4734451A (en) * | 1983-09-01 | 1988-03-29 | Battelle Memorial Institute | Supercritical fluid molecular spray thin films and fine powders |
US6309669B1 (en) | 1984-03-16 | 2001-10-30 | The United States Of America As Represented By The Secretary Of The Army | Therapeutic treatment and prevention of infections with a bioactive materials encapsulated within a biodegradable-biocompatible polymeric matrix |
US5102417A (en) | 1985-11-07 | 1992-04-07 | Expandable Grafts Partnership | Expandable intraluminal graft, and method and apparatus for implanting an expandable intraluminal graft |
US4985625A (en) * | 1986-03-06 | 1991-01-15 | Finnigan Corporation | Transfer line for mass spectrometer apparatus |
US4762593A (en) | 1986-06-13 | 1988-08-09 | Youngner Philip G | Distilling apparatus |
US4758435A (en) | 1986-08-11 | 1988-07-19 | American Cyanamid Company | Estradiol implant composition and method for preparation |
JPH068902Y2 (ja) | 1988-04-19 | 1994-03-09 | マツダ株式会社 | 車両用始動安全装置 |
US5106650A (en) * | 1988-07-14 | 1992-04-21 | Union Carbide Chemicals & Plastics Technology Corporation | Electrostatic liquid spray application of coating with supercritical fluids as diluents and spraying from an orifice |
US4950239A (en) | 1988-08-09 | 1990-08-21 | Worldwide Medical Plastics Inc. | Angioplasty balloons and balloon catheters |
ATE121954T1 (de) | 1988-08-24 | 1995-05-15 | Marvin J Slepian | Endoluminale dichtung mit bisdegradierbaren polymeren. |
US4931037A (en) | 1988-10-13 | 1990-06-05 | International Medical, Inc. | In-dwelling ureteral stent and injection stent assembly, and method of using same |
US4958625A (en) | 1989-07-18 | 1990-09-25 | Boston Scientific Corporation | Biopsy needle instrument |
DE69002295T2 (de) | 1989-09-25 | 1993-11-04 | Schneider Usa Inc | Mehrschichtextrusion als verfahren zur herstellung von ballons zur gefaessplastik. |
CA2026604A1 (fr) | 1989-10-02 | 1991-04-03 | Rodney G. Wolff | Drain articule |
US5000519A (en) * | 1989-11-24 | 1991-03-19 | John Moore | Towed vehicle emergency brake control system |
US5674192A (en) | 1990-12-28 | 1997-10-07 | Boston Scientific Corporation | Drug delivery |
JP2641781B2 (ja) * | 1990-02-23 | 1997-08-20 | シャープ株式会社 | 半導体素子分離領域の形成方法 |
US5545208A (en) | 1990-02-28 | 1996-08-13 | Medtronic, Inc. | Intralumenal drug eluting prosthesis |
US5360403A (en) | 1990-05-16 | 1994-11-01 | Lake Region Manufacturing Co., Inc. | Balloon catheter with lumen occluder |
WO1991017724A1 (fr) | 1990-05-17 | 1991-11-28 | Harbor Medical Devices, Inc. | Polymere utilise dans un dispositif medical |
US5320634A (en) | 1990-07-03 | 1994-06-14 | Interventional Technologies, Inc. | Balloon catheter with seated cutting edges |
US5090419A (en) * | 1990-08-23 | 1992-02-25 | Aubrey Palestrant | Apparatus for acquiring soft tissue biopsy specimens |
US6248129B1 (en) | 1990-09-14 | 2001-06-19 | Quanam Medical Corporation | Expandable polymeric stent with memory and delivery apparatus and method |
US6524698B1 (en) | 1990-09-27 | 2003-02-25 | Helmuth Schmoock | Fluid impermeable foil |
CA2060635A1 (fr) | 1991-02-12 | 1992-08-13 | Keith D'alessio | Implants medicaux bioabsorbables |
GB2253164B (en) | 1991-02-22 | 1994-10-05 | Hoechst Uk Ltd | Improvements in or relating to electrostatic coating of substrates of medicinal products |
US5158986A (en) | 1991-04-05 | 1992-10-27 | Massachusetts Institute Of Technology | Microcellular thermoplastic foamed with supercritical fluid |
US5195969A (en) * | 1991-04-26 | 1993-03-23 | Boston Scientific Corporation | Co-extruded medical balloons and catheter using such balloons |
US5372676A (en) | 1991-05-15 | 1994-12-13 | Lowe; Michael | Method for producing replicated paving stone |
US5185776A (en) | 1991-08-05 | 1993-02-09 | Townsend Boyd E | Cover for an x-ray cassette |
US5356433A (en) | 1991-08-13 | 1994-10-18 | Cordis Corporation | Biocompatible metal surfaces |
US5243023A (en) | 1991-08-28 | 1993-09-07 | The United States Of America As Represented By The Administrator Of The National Aeronautics And Space Administration | Polyimides containing amide and perfluoroisopropylidene connecting groups |
US5366504A (en) | 1992-05-20 | 1994-11-22 | Boston Scientific Corporation | Tubular medical prosthesis |
JPH0698902A (ja) | 1991-11-22 | 1994-04-12 | Janome Sewing Mach Co Ltd | 骨インプラントの製造方法 |
US5125570A (en) | 1991-12-30 | 1992-06-30 | Robert Jones | Delivery box signal device |
US5697882A (en) * | 1992-01-07 | 1997-12-16 | Arthrocare Corporation | System and method for electrosurgical cutting and ablation |
US5876452A (en) | 1992-02-14 | 1999-03-02 | Board Of Regents, University Of Texas System | Biodegradable implant |
JPH07505316A (ja) * | 1992-03-31 | 1995-06-15 | ボストン サイエンティフィック コーポレーション | 医療用ワイヤ |
US5288711A (en) * | 1992-04-28 | 1994-02-22 | American Home Products Corporation | Method of treating hyperproliferative vascular disease |
US5514379A (en) | 1992-08-07 | 1996-05-07 | The General Hospital Corporation | Hydrogel compositions and methods of use |
US5342621A (en) | 1992-09-15 | 1994-08-30 | Advanced Cardiovascular Systems, Inc. | Antithrombogenic surface |
US5500180A (en) * | 1992-09-30 | 1996-03-19 | C. R. Bard, Inc. | Method of making a distensible dilatation balloon using a block copolymer |
GB9221220D0 (en) | 1992-10-09 | 1992-11-25 | Sandoz Ag | Organic componds |
US5387313A (en) | 1992-11-09 | 1995-02-07 | Bmc Industries, Inc. | Etchant control system |
US5385776A (en) * | 1992-11-16 | 1995-01-31 | Alliedsignal Inc. | Nanocomposites of gamma phase polymers containing inorganic particulate material |
EP0604022A1 (fr) * | 1992-12-22 | 1994-06-29 | Advanced Cardiovascular Systems, Inc. | Endoprothèse résorbable, à plusieurs couches, pour le maintien des vaisseaux, et sa méthode de fabrication |
US5324049A (en) | 1992-12-23 | 1994-06-28 | Xerox Corporation | Mandrel with flared, dish shaped disk and process for using mandrel |
BR9307814A (pt) | 1993-01-19 | 1995-11-14 | Schneider Usa Inc | Dispositivo protético compósito blindado |
US5981568A (en) | 1993-01-28 | 1999-11-09 | Neorx Corporation | Therapeutic inhibitor of vascular smooth muscle cells |
US5340614A (en) | 1993-02-11 | 1994-08-23 | Minnesota Mining And Manufacturing Company | Methods of polymer impregnation |
US6228879B1 (en) * | 1997-10-16 | 2001-05-08 | The Children's Medical Center | Methods and compositions for inhibition of angiogenesis |
CA2157793C (fr) | 1993-03-09 | 1999-07-13 | James E. Woiszwillo | Microparticules macromoleculaires et methode de production |
US6090925A (en) | 1993-03-09 | 2000-07-18 | Epic Therapeutics, Inc. | Macromolecular microparticles and methods of production and use |
US5981719A (en) | 1993-03-09 | 1999-11-09 | Epic Therapeutics, Inc. | Macromolecular microparticles and methods of production and use |
JPH08507715A (ja) | 1993-03-18 | 1996-08-20 | シーダーズ サイナイ メディカル センター | 生体人工部材のための薬剤導入性および放出性重合性コーティング |
US20020055710A1 (en) | 1998-04-30 | 2002-05-09 | Ronald J. Tuch | Medical device for delivering a therapeutic agent and method of preparation |
US5403347A (en) * | 1993-05-27 | 1995-04-04 | United States Surgical Corporation | Absorbable block copolymers and surgical articles fabricated therefrom |
US5350627A (en) | 1993-06-11 | 1994-09-27 | Camelot Technologies, Inc. | Coated webs |
US5380299A (en) | 1993-08-30 | 1995-01-10 | Med Institute, Inc. | Thrombolytic treated intravascular medical device |
DE4336209C2 (de) | 1993-09-10 | 1995-09-21 | Michael Dr Simon | Verfahren zur Herstellung einer mit antithrombotischen Agenzien beschichteten Gefäßprothese |
US5632772A (en) | 1993-10-21 | 1997-05-27 | Corvita Corporation | Expandable supportive branched endoluminal grafts |
US5350361A (en) | 1993-11-10 | 1994-09-27 | Medtronic, Inc. | Tri-fold balloon for dilatation catheter and related method |
US5494620A (en) * | 1993-11-24 | 1996-02-27 | United States Surgical Corporation | Method of manufacturing a monofilament suture |
US5626611A (en) * | 1994-02-10 | 1997-05-06 | United States Surgical Corporation | Composite bioabsorbable materials and surgical articles made therefrom |
US6146356A (en) | 1994-03-02 | 2000-11-14 | Scimed Life Systems, Inc. | Block copolymer elastomer catheter balloons |
DE69514910T3 (de) | 1994-03-02 | 2009-09-24 | Boston Scientific Ltd., Hastings Christ Church | Blockcopolymerelastomer ballon für katheter |
US5733303A (en) | 1994-03-17 | 1998-03-31 | Medinol Ltd. | Flexible expandable stent |
US5843120A (en) | 1994-03-17 | 1998-12-01 | Medinol Ltd. | Flexible-expandable stent |
US5362718A (en) | 1994-04-18 | 1994-11-08 | American Home Products Corporation | Rapamycin hydroxyesters |
JPH10503179A (ja) | 1994-06-24 | 1998-03-24 | イミュネックス・コーポレーション | 放出制御性ポリペプチド組成物および炎症性腸疾患の治療方法 |
JP3672314B2 (ja) | 1994-07-12 | 2005-07-20 | バーウィンド・ファーマスーティカル・サーヴィスィーズ・インコーポレーテッド | 防湿性フィルム被覆材組成物、方法および被覆成形物 |
US5626862A (en) * | 1994-08-02 | 1997-05-06 | Massachusetts Institute Of Technology | Controlled local delivery of chemotherapeutic agents for treating solid tumors |
NL9401690A (nl) | 1994-10-13 | 1996-05-01 | Industrial Res Bv | In een lichaamsvat implanteerbare stent. |
CA2206734A1 (fr) | 1994-12-02 | 1996-06-06 | Science Incorporated | Doseur de medicaments |
WO1996020698A2 (fr) | 1995-01-05 | 1996-07-11 | The Board Of Regents Acting For And On Behalf Of The University Of Michigan | Nanoparticules a modification de surface et leurs procedes de fabrication et d'utilisation |
US5599576A (en) | 1995-02-06 | 1997-02-04 | Surface Solutions Laboratories, Inc. | Medical apparatus with scratch-resistant coating and method of making same |
US6231600B1 (en) * | 1995-02-22 | 2001-05-15 | Scimed Life Systems, Inc. | Stents with hybrid coating for medical devices |
US5605696A (en) | 1995-03-30 | 1997-02-25 | Advanced Cardiovascular Systems, Inc. | Drug loaded polymeric material and method of manufacture |
WO1996032907A1 (fr) | 1995-04-19 | 1996-10-24 | Schneider (Usa) Inc. | Extenseur avec un revetement capable de liberer un medicament |
US5837313A (en) | 1995-04-19 | 1998-11-17 | Schneider (Usa) Inc | Drug release stent coating process |
US6120536A (en) | 1995-04-19 | 2000-09-19 | Schneider (Usa) Inc. | Medical devices with long term non-thrombogenic coatings |
US5570537A (en) | 1995-04-27 | 1996-11-05 | Black; Douglas A. | Electronic insecticidal cable |
CN1136922C (zh) | 1995-05-01 | 2004-02-04 | 株式会社三养社 | 可植入的可生物再吸收的膜及其制备方法 |
US6602281B1 (en) | 1995-06-05 | 2003-08-05 | Avantec Vascular Corporation | Radially expansible vessel scaffold having beams and expansion joints |
US5674242A (en) | 1995-06-06 | 1997-10-07 | Quanam Medical Corporation | Endoprosthetic device with therapeutic compound |
US5714007A (en) | 1995-06-06 | 1998-02-03 | David Sarnoff Research Center, Inc. | Apparatus for electrostatically depositing a medicament powder upon predefined regions of a substrate |
US6774278B1 (en) | 1995-06-07 | 2004-08-10 | Cook Incorporated | Coated implantable medical device |
AU716005B2 (en) | 1995-06-07 | 2000-02-17 | Cook Medical Technologies Llc | Implantable medical device |
US5609629A (en) * | 1995-06-07 | 1997-03-11 | Med Institute, Inc. | Coated implantable medical device |
CA2219659C (fr) | 1995-06-09 | 2008-03-18 | Novartis Ag | Derives de rapamycine |
US6256529B1 (en) * | 1995-07-26 | 2001-07-03 | Burdette Medical Systems, Inc. | Virtual reality 3D visualization for surgical procedures |
JP3476604B2 (ja) | 1995-08-22 | 2003-12-10 | 鐘淵化学工業株式会社 | 薬剤を付着・コーティングしたステントの製造方法 |
DE69600289T2 (de) | 1995-09-19 | 1998-09-03 | Mitsubishi Gas Chemical Co | Biologisch abbaubares wasserlösliches Polymer |
US5607442A (en) | 1995-11-13 | 1997-03-04 | Isostent, Inc. | Stent with improved radiopacity and appearance characteristics |
CA2192520A1 (fr) | 1996-03-05 | 1997-09-05 | Ian M. Penn | Tringle extensible et methode de mise en place de ladite tringle |
US6461644B1 (en) | 1996-03-25 | 2002-10-08 | Richard R. Jackson | Anesthetizing plastics, drug delivery plastics, and related medical products, systems and methods |
NZ331269A (en) | 1996-04-10 | 2000-01-28 | Advanced Cardiovascular System | Expandable stent, its structural strength varying along its length |
US5669932A (en) | 1996-05-29 | 1997-09-23 | Isostent, Inc. | Means for accurately positioning an expandable stent |
DK0903389T3 (da) | 1996-05-31 | 2010-01-18 | Toto Ltd | Antifouling-element og antifouling-coating-sammensætning |
US6143037A (en) | 1996-06-12 | 2000-11-07 | The Regents Of The University Of Michigan | Compositions and methods for coating medical devices |
US5876426A (en) * | 1996-06-13 | 1999-03-02 | Scimed Life Systems, Inc. | System and method of providing a blood-free interface for intravascular light delivery |
FR2750897B1 (fr) | 1996-07-10 | 1998-09-18 | Sames Sa | Projecteur triboelectrique, installation de projection de produit de revetement et procede de commande d'un tel projecteur |
US6258823B1 (en) | 1996-07-12 | 2001-07-10 | Ariad Pharmaceuticals, Inc. | Materials and method for treating or preventing pathogenic fungal infection |
JPH1029524A (ja) | 1996-07-15 | 1998-02-03 | Toyota Motor Corp | 車輪スリップ制御装置 |
US5871436A (en) | 1996-07-19 | 1999-02-16 | Advanced Cardiovascular Systems, Inc. | Radiation therapy method and device |
EP0820784B1 (fr) | 1996-07-24 | 2003-06-11 | Cordis Corporation | Cathéter à ballon et méthode de son emploie |
US6013855A (en) * | 1996-08-06 | 2000-01-11 | United States Surgical | Grafting of biocompatible hydrophilic polymers onto inorganic and metal surfaces |
DE19633901A1 (de) | 1996-08-22 | 1998-02-26 | Thomas Prof Dr Med Ischinger | Gefäßstütze in Form einer Schlauchabschnitts-artigen Stützstruktur |
US6884377B1 (en) | 1996-08-27 | 2005-04-26 | Trexel, Inc. | Method and apparatus for microcellular polymer extrusion |
US5807404A (en) | 1996-09-19 | 1998-09-15 | Medinol Ltd. | Stent with variable features to optimize support and method of making such stent |
US6193963B1 (en) | 1996-10-17 | 2001-02-27 | The Regents Of The University Of California | Method of treating tumor-bearing patients with human plasma hyaluronidase |
US6387121B1 (en) * | 1996-10-21 | 2002-05-14 | Inflow Dynamics Inc. | Vascular and endoluminal stents with improved coatings |
US6530951B1 (en) * | 1996-10-24 | 2003-03-11 | Cook Incorporated | Silver implantable medical device |
GB9623634D0 (en) | 1996-11-13 | 1997-01-08 | Bpsi Holdings Inc | Method and apparatus for the coating of substrates for pharmaceutical use |
US6251980B1 (en) | 1996-12-06 | 2001-06-26 | Amcol International Corporation | Nanocomposites formed by onium ion-intercalated clay and rigid anhydride-cured epoxy resins |
US5871437A (en) | 1996-12-10 | 1999-02-16 | Inflow Dynamics, Inc. | Radioactive stent for treating blood vessels to prevent restenosis |
US6517860B1 (en) | 1996-12-31 | 2003-02-11 | Quadrant Holdings Cambridge, Ltd. | Methods and compositions for improved bioavailability of bioactive agents for mucosal delivery |
FR2758253B1 (fr) | 1997-01-10 | 1999-04-02 | Nycomed Lab Sa | Dispositif implantable pour le traitement d'un conduit corporel |
US6884823B1 (en) | 1997-01-16 | 2005-04-26 | Trexel, Inc. | Injection molding of polymeric material |
DE29702671U1 (de) | 1997-02-17 | 1997-04-10 | Jomed Implantate GmbH, 72414 Rangendingen | Stent |
ES2388248T3 (es) | 1997-03-31 | 2012-10-11 | Boston Scientific Scimed Limited | Forma de dosificación que comprende taxol en forma cristalina |
US6240616B1 (en) | 1997-04-15 | 2001-06-05 | Advanced Cardiovascular Systems, Inc. | Method of manufacturing a medicated porous metal prosthesis |
US8172897B2 (en) * | 1997-04-15 | 2012-05-08 | Advanced Cardiovascular Systems, Inc. | Polymer and metal composite implantable medical devices |
US6273913B1 (en) | 1997-04-18 | 2001-08-14 | Cordis Corporation | Modified stent useful for delivery of drugs along stent strut |
IT1292295B1 (it) | 1997-04-29 | 1999-01-29 | Sorin Biomedica Cardio Spa | Stent per angioplastica |
FR2762777B1 (fr) | 1997-05-05 | 1999-10-22 | Patrick Sabaria | Extenseurs vasculaires et coronaires, habituellement designes sous le nom de "stent" |
GB9800936D0 (en) | 1997-05-10 | 1998-03-11 | Univ Nottingham | Biofunctional polymers |
WO1998051238A1 (fr) | 1997-05-14 | 1998-11-19 | Novo Rps Ulc | Prothese endovasculaire extensible et son procede de production |
DE19720115C2 (de) | 1997-05-14 | 1999-05-20 | Jomed Implantate Gmbh | Stent-Graft |
DE29708689U1 (de) | 1997-05-15 | 1997-07-17 | Jomed Implantate GmbH, 72414 Rangendingen | Koronarer Stent |
US5913895A (en) | 1997-06-02 | 1999-06-22 | Isostent, Inc. | Intravascular stent with enhanced rigidity strut members |
US6416779B1 (en) | 1997-06-11 | 2002-07-09 | Umd, Inc. | Device and method for intravaginal or transvaginal treatment of fungal, bacterial, viral or parasitic infections |
US6433154B1 (en) | 1997-06-12 | 2002-08-13 | Bristol-Myers Squibb Company | Functional receptor/kinase chimera in yeast cells |
US6245103B1 (en) | 1997-08-01 | 2001-06-12 | Schneider (Usa) Inc | Bioabsorbable self-expanding stent |
US6077880A (en) | 1997-08-08 | 2000-06-20 | Cordis Corporation | Highly radiopaque polyolefins and method for making the same |
AU8782098A (en) | 1997-08-13 | 1999-03-08 | Boston Scientific Limited | Loading and release of water-insoluble drugs |
DE69832089T2 (de) | 1997-08-28 | 2006-07-20 | Nissan Chemical Industries, Ltd. | Mittel zur förderung und verstärkung der neovaskularisierung |
DE29716476U1 (de) | 1997-09-13 | 1997-12-18 | Convent, Gerd, 47829 Krefeld | Stent zur Stenosebehandlung |
DE29716467U1 (de) | 1997-09-15 | 1998-02-26 | Rittal-Werk Rudolf Loh Gmbh & Co Kg, 35745 Herborn | Gehäuseaufbau für elektrische oder elektronische Einbauten |
US7378105B2 (en) * | 1997-09-26 | 2008-05-27 | Abbott Laboratories | Drug delivery systems, kits, and methods for administering zotarolimus and paclitaxel to blood vessel lumens |
US8257725B2 (en) | 1997-09-26 | 2012-09-04 | Abbott Laboratories | Delivery of highly lipophilic agents via medical devices |
TW557297B (en) | 1997-09-26 | 2003-10-11 | Abbott Lab | Rapamycin analogs having immunomodulatory activity, and pharmaceutical compositions containing same |
US6042606A (en) | 1997-09-29 | 2000-03-28 | Cook Incorporated | Radially expandable non-axially contracting surgical stent |
US6071308A (en) | 1997-10-01 | 2000-06-06 | Boston Scientific Corporation | Flexible metal wire stent |
US6127000A (en) | 1997-10-10 | 2000-10-03 | North Carolina State University | Method and compositions for protecting civil infrastructure |
IE980920A1 (en) | 1997-11-07 | 1999-05-19 | Salviac Ltd | An embolic protection device |
US6635269B1 (en) * | 1997-11-24 | 2003-10-21 | Morphoplant Gmbh | Immobilizing mediator molecules via anchor molecules on metallic implant materials containing oxide layer |
US5957975A (en) | 1997-12-15 | 1999-09-28 | The Cleveland Clinic Foundation | Stent having a programmed pattern of in vivo degradation |
JP2002500065A (ja) | 1998-01-06 | 2002-01-08 | バイオアミド・インコーポレイテッド | 生体吸収性繊維およびそれから製造される強化コンポジット |
US6129755A (en) | 1998-01-09 | 2000-10-10 | Nitinol Development Corporation | Intravascular stent having an improved strut configuration |
ATE326919T1 (de) | 1998-03-04 | 2006-06-15 | Boston Scient Ltd | Stent mit verbesserter zellenkonfiguration |
US7208010B2 (en) * | 2000-10-16 | 2007-04-24 | Conor Medsystems, Inc. | Expandable medical device for delivery of beneficial agent |
SE9801288D0 (sv) | 1998-04-14 | 1998-04-14 | Astra Ab | Vaccine delivery system and metod of production |
US8029561B1 (en) | 2000-05-12 | 2011-10-04 | Cordis Corporation | Drug combination useful for prevention of restenosis |
GB9808052D0 (en) | 1998-04-17 | 1998-06-17 | Secr Defence | Implants for administering substances and methods of producing implants |
US6206914B1 (en) * | 1998-04-30 | 2001-03-27 | Medtronic, Inc. | Implantable system with drug-eluting cells for on-demand local drug delivery |
US6190699B1 (en) | 1998-05-08 | 2001-02-20 | Nzl Corporation | Method of incorporating proteins or peptides into a matrix and administration thereof through mucosa |
DE19822157B4 (de) | 1998-05-16 | 2013-01-10 | Abbott Laboratories Vascular Enterprises Ltd. | Radial aufweitbarer Stent zur Implantierung in ein Körpergefäß |
FR2780057B1 (fr) | 1998-06-18 | 2002-09-13 | Sanofi Sa | Phenoxypropanolamines, procede pour leur preparation et compositions pharmaceutiques les contenant |
EP1087800B1 (fr) | 1998-06-19 | 2003-08-06 | Oxibio, Inc. | Dispositif medical implantable a proprietes anti-infectieuses et contraceptives |
US6541033B1 (en) * | 1998-06-30 | 2003-04-01 | Amgen Inc. | Thermosensitive biodegradable hydrogels for sustained delivery of leptin |
US6153252A (en) | 1998-06-30 | 2000-11-28 | Ethicon, Inc. | Process for coating stents |
US7004962B2 (en) | 1998-07-27 | 2006-02-28 | Schneider (Usa), Inc. | Neuroaneurysm occlusion and delivery device and method of using same |
US8070796B2 (en) * | 1998-07-27 | 2011-12-06 | Icon Interventional Systems, Inc. | Thrombosis inhibiting graft |
US7967855B2 (en) | 1998-07-27 | 2011-06-28 | Icon Interventional Systems, Inc. | Coated medical device |
US6461380B1 (en) | 1998-07-28 | 2002-10-08 | Advanced Cardiovascular Systems, Inc. | Stent configuration |
US6248127B1 (en) | 1998-08-21 | 2001-06-19 | Medtronic Ave, Inc. | Thromboresistant coated medical device |
US6193744B1 (en) | 1998-09-10 | 2001-02-27 | Scimed Life Systems, Inc. | Stent configurations |
US6342062B1 (en) * | 1998-09-24 | 2002-01-29 | Scimed Life Systems, Inc. | Retrieval devices for vena cava filter |
US6363104B1 (en) | 1998-10-02 | 2002-03-26 | Ericsson Inc. | Method and apparatus for interference cancellation in a rake receiver |
US6245104B1 (en) | 1999-02-28 | 2001-06-12 | Inflow Dynamics Inc. | Method of fabricating a biocompatible stent |
US6042597A (en) | 1998-10-23 | 2000-03-28 | Scimed Life Systems, Inc. | Helical stent design |
US6143314A (en) | 1998-10-28 | 2000-11-07 | Atrix Laboratories, Inc. | Controlled release liquid delivery compositions with low initial drug burst |
FR2785174A1 (fr) | 1998-11-03 | 2000-05-05 | Jacques Seguin | Extenseur de conduit corporel, notamment vasculaire |
US6355691B1 (en) * | 1998-11-12 | 2002-03-12 | Tobias M. Goodman | Urushiol therapy of transitional cell carcinoma of the bladder |
CA2353606A1 (fr) | 1998-12-03 | 2000-06-08 | Boston Scientific Limited | Endoprothese comportant en surface un principe actif sous forme de cristaux |
US6372246B1 (en) | 1998-12-16 | 2002-04-16 | Ortho-Mcneil Pharmaceutical, Inc. | Polyethylene glycol coating for electrostatic dry deposition of pharmaceuticals |
US6858598B1 (en) | 1998-12-23 | 2005-02-22 | G. D. Searle & Co. | Method of using a matrix metalloproteinase inhibitor and one or more antineoplastic agents as a combination therapy in the treatment of neoplasia |
US6147135A (en) | 1998-12-31 | 2000-11-14 | Ethicon, Inc. | Fabrication of biocompatible polymeric composites |
US6638727B1 (en) | 1999-01-26 | 2003-10-28 | Cytyc Health Corporation | Methods for identifying treating or monitoring asymptomatic patients for risk reduction or therapeutic treatment of breast cancer |
US6706283B1 (en) * | 1999-02-10 | 2004-03-16 | Pfizer Inc | Controlled release by extrusion of solid amorphous dispersions of drugs |
SE9900519D0 (sv) | 1999-02-17 | 1999-02-17 | Lars Lidgren | A method for the preparation of UHMWPE doped with an antioxidant and an implant made thereof |
US6171327B1 (en) * | 1999-02-24 | 2001-01-09 | Scimed Life Systems, Inc. | Intravascular filter and method |
US6364903B2 (en) | 1999-03-19 | 2002-04-02 | Meadox Medicals, Inc. | Polymer coated stent |
SE9901002D0 (sv) | 1999-03-19 | 1999-03-19 | Electrolux Ab | Anordning för rengöring av textilföremål med en förtätad vätskeformig behandlingsgas |
US6368658B1 (en) | 1999-04-19 | 2002-04-09 | Scimed Life Systems, Inc. | Coating medical devices using air suspension |
US6923979B2 (en) | 1999-04-27 | 2005-08-02 | Microdose Technologies, Inc. | Method for depositing particles onto a substrate using an alternating electric field |
US8016873B1 (en) | 1999-05-03 | 2011-09-13 | Drasler William J | Intravascular hinge stent |
JP2000316981A (ja) | 1999-05-14 | 2000-11-21 | Kawasumi Lab Inc | ステント |
US6726712B1 (en) * | 1999-05-14 | 2004-04-27 | Boston Scientific Scimed | Prosthesis deployment device with translucent distal end |
US6815218B1 (en) * | 1999-06-09 | 2004-11-09 | Massachusetts Institute Of Technology | Methods for manufacturing bioelectronic devices |
CN1390126B (zh) | 1999-07-06 | 2012-06-13 | 恩多研究公司 | 选择性雌激素受体调节剂在制备用于治疗或降低肥胖症发展危险性的药物中的用途 |
AU783158B2 (en) | 1999-08-24 | 2005-09-29 | Ariad Pharmaceuticals, Inc. | 28-epirapalogs |
US6146404A (en) | 1999-09-03 | 2000-11-14 | Scimed Life Systems, Inc. | Removable thrombus filter |
US20070032853A1 (en) | 2002-03-27 | 2007-02-08 | Hossainy Syed F | 40-O-(2-hydroxy)ethyl-rapamycin coated stent |
US6358557B1 (en) | 1999-09-10 | 2002-03-19 | Sts Biopolymers, Inc. | Graft polymerization of substrate surfaces |
US6610013B1 (en) | 1999-10-01 | 2003-08-26 | Life Imaging Systems, Inc. | 3D ultrasound-guided intraoperative prostate brachytherapy |
US6755871B2 (en) | 1999-10-15 | 2004-06-29 | R.R. Street & Co. Inc. | Cleaning system utilizing an organic cleaning solvent and a pressurized fluid solvent |
US6458387B1 (en) | 1999-10-18 | 2002-10-01 | Epic Therapeutics, Inc. | Sustained release microspheres |
US7537785B2 (en) * | 1999-10-29 | 2009-05-26 | Nitromed, Inc. | Composition for treating vascular diseases characterized by nitric oxide insufficiency |
US6537310B1 (en) * | 1999-11-19 | 2003-03-25 | Advanced Bio Prosthetic Surfaces, Ltd. | Endoluminal implantable devices and method of making same |
US6908624B2 (en) * | 1999-12-23 | 2005-06-21 | Advanced Cardiovascular Systems, Inc. | Coating for implantable devices and a method of forming the same |
US6572813B1 (en) | 2000-01-13 | 2003-06-03 | Advanced Cardiovascular Systems, Inc. | Balloon forming process |
TWI284048B (en) | 2000-01-27 | 2007-07-21 | Zentaris Ag | Compressed microparticles for dry injection |
EP1132058A1 (fr) | 2000-03-06 | 2001-09-12 | Advanced Laser Applications Holding S.A. | Prothèse intravasculaire |
EP1145719A3 (fr) | 2000-03-10 | 2001-11-14 | Pfizer Products Inc. | Utilisation d'un sel ferreux pour l'inhibition de la dégradation oxydative de compositions pharmaceutiques |
US8088060B2 (en) * | 2000-03-15 | 2012-01-03 | Orbusneich Medical, Inc. | Progenitor endothelial cell capturing with a drug eluting implantable medical device |
CN2423899Y (zh) | 2000-05-08 | 2001-03-21 | 微创医疗器械(上海)有限公司 | 冠状动脉支架 |
AU6145501A (en) * | 2000-05-12 | 2001-11-26 | Advanced Bio Prosthetic Surfac | Self-supporting laminated films, structural materials and medical devices manufactured therefrom and methods of making same |
JP4786113B2 (ja) | 2000-05-16 | 2011-10-05 | オーソーマクニール ファーマシューティカル, インコーポレイテッド | 超臨界二酸化炭素を用いる医療用装置のコーティング方法 |
US7217770B2 (en) | 2000-05-17 | 2007-05-15 | Samyang Corporation | Stable polymeric micelle-type drug composition and method for the preparation thereof |
US20030077200A1 (en) * | 2000-07-07 | 2003-04-24 | Craig Charles H. | Enhanced radiopaque alloy stent |
US20020144757A1 (en) | 2000-07-07 | 2002-10-10 | Craig Charles Horace | Stainless steel alloy with improved radiopaque characteristics |
CN102871979B (zh) | 2000-09-01 | 2014-10-22 | 帕尔马亚有限公司 | 缓释药物制剂及其施用方法 |
US7332242B2 (en) | 2000-09-01 | 2008-02-19 | Itochu Corporation | Lithium-based battery having extensible, ion-impermeable polymer covering on the battery container |
US6362718B1 (en) | 2000-09-06 | 2002-03-26 | Stephen L. Patrick | Motionless electromagnetic generator |
US6521258B1 (en) | 2000-09-08 | 2003-02-18 | Ferro Corporation | Polymer matrices prepared by supercritical fluid processing techniques |
US6506213B1 (en) | 2000-09-08 | 2003-01-14 | Ferro Corporation | Manufacturing orthopedic parts using supercritical fluid processing techniques |
US6953560B1 (en) | 2000-09-28 | 2005-10-11 | Advanced Cardiovascular Systems, Inc. | Barriers for polymer-coated implantable medical devices and methods for making the same |
US20060222756A1 (en) | 2000-09-29 | 2006-10-05 | Cordis Corporation | Medical devices, drug coatings and methods of maintaining the drug coatings thereon |
US20020111590A1 (en) | 2000-09-29 | 2002-08-15 | Davila Luis A. | Medical devices, drug coatings and methods for maintaining the drug coatings thereon |
WO2002026281A1 (fr) | 2000-09-29 | 2002-04-04 | Cordis Corporation | Dispositifs medicaux avec enrobages |
JP2004537495A (ja) | 2000-11-03 | 2004-12-16 | コントロール・デリバリー・システムズ | 関節疾患を治療するための改善された装置及び方法 |
US20050084514A1 (en) | 2000-11-06 | 2005-04-21 | Afmedica, Inc. | Combination drug therapy for reducing scar tissue formation |
US20040018228A1 (en) | 2000-11-06 | 2004-01-29 | Afmedica, Inc. | Compositions and methods for reducing scar tissue formation |
AU2002239491A1 (en) | 2000-11-09 | 2002-05-27 | Vanderbilt University | Methods for the treatment of cancer and other diseases and methods of developing the same |
US6682757B1 (en) * | 2000-11-16 | 2004-01-27 | Euro-Celtique, S.A. | Titratable dosage transdermal delivery system |
KR20020076265A (ko) | 2000-11-30 | 2002-10-09 | 가부시키가이샤 이가키 이료 세케이 | 혈관용 스텐트 및 혈관용 스텐트용 소재 |
US6913617B1 (en) * | 2000-12-27 | 2005-07-05 | Advanced Cardiovascular Systems, Inc. | Method for creating a textured surface on an implantable medical device |
GB0100761D0 (en) | 2001-01-11 | 2001-02-21 | Biocompatibles Ltd | Drug delivery from stents |
GB0100760D0 (en) | 2001-01-11 | 2001-02-21 | Biocompatibles Ltd | Drug delivery from stents |
WO2002059184A2 (fr) | 2001-01-24 | 2002-08-01 | Virginia Commonwealth University | Impression moleculaire de petites particules et production de petites particules a partir de reactifs solides |
US20040220660A1 (en) | 2001-02-05 | 2004-11-04 | Shanley John F. | Bioresorbable stent with beneficial agent reservoirs |
DE10106810A1 (de) | 2001-02-14 | 2002-09-05 | Siemens Ag | Netzunabhängige Stromversorgungseinheit |
US6905555B2 (en) | 2001-02-15 | 2005-06-14 | Micell Technologies, Inc. | Methods for transferring supercritical fluids in microelectronic and other industrial processes |
US6720003B2 (en) | 2001-02-16 | 2004-04-13 | Andrx Corporation | Serotonin reuptake inhibitor formulations |
US6811549B2 (en) | 2001-02-16 | 2004-11-02 | William H. Fleming | Administration of therapeutic or diagnostic agents using interlabial pad |
JP2002239013A (ja) | 2001-02-21 | 2002-08-27 | Terumo Corp | ステント及びその製造方法 |
US6949251B2 (en) | 2001-03-02 | 2005-09-27 | Stryker Corporation | Porous β-tricalcium phosphate granules for regeneration of bone tissue |
WO2002074194A2 (fr) | 2001-03-16 | 2002-09-26 | Sts Biopolymers, Inc. | Revetement polymere multicouche medicamenteux |
US7771468B2 (en) | 2001-03-16 | 2010-08-10 | Angiotech Biocoatings Corp. | Medicated stent having multi-layer polymer coating |
WO2002085188A2 (fr) | 2001-04-24 | 2002-10-31 | Kaplan Edward J | Dispositif d'implantation flexible et son procede d'utilisation |
US20040022853A1 (en) | 2001-04-26 | 2004-02-05 | Control Delivery Systems, Inc. | Polymer-based, sustained release drug delivery system |
US7247338B2 (en) | 2001-05-16 | 2007-07-24 | Regents Of The University Of Minnesota | Coating medical devices |
WO2002096389A1 (fr) | 2001-05-30 | 2002-12-05 | Microchips, Inc. | Dispositifs reservoirs a micropuce pourvus d'un revetement conforme |
US7201940B1 (en) | 2001-06-12 | 2007-04-10 | Advanced Cardiovascular Systems, Inc. | Method and apparatus for thermal spray processing of medical devices |
US20030044514A1 (en) | 2001-06-13 | 2003-03-06 | Richard Robert E. | Using supercritical fluids to infuse therapeutic on a medical device |
US7485113B2 (en) * | 2001-06-22 | 2009-02-03 | Johns Hopkins University | Method for drug delivery through the vitreous humor |
US7501157B2 (en) | 2001-06-26 | 2009-03-10 | Accelr8 Technology Corporation | Hydroxyl functional surface coating |
US6967234B2 (en) | 2002-12-18 | 2005-11-22 | Ethicon, Inc. | Alkyd-lactone copolymers for medical applications |
US6585755B2 (en) | 2001-06-29 | 2003-07-01 | Advanced Cardiovascular | Polymeric stent suitable for imaging by MRI and fluoroscopy |
US7015875B2 (en) * | 2001-06-29 | 2006-03-21 | Novus Partners Llc | Dynamic device for billboard advertising |
US6743505B2 (en) | 2001-07-27 | 2004-06-01 | Ethicon, Inc. | Bioabsorbable multifilament yarn and methods of manufacture |
US6723913B1 (en) * | 2001-08-23 | 2004-04-20 | Anthony T. Barbetta | Fan cooling of active speakers |
US6669980B2 (en) | 2001-09-18 | 2003-12-30 | Scimed Life Systems, Inc. | Method for spray-coating medical devices |
CN1568166A (zh) | 2001-10-15 | 2005-01-19 | 荷姆泰克股份有限公司 | 预防再狭窄的涂层支架 |
US20030088307A1 (en) * | 2001-11-05 | 2003-05-08 | Shulze John E. | Potent coatings for stents |
US6939376B2 (en) | 2001-11-05 | 2005-09-06 | Sun Biomedical, Ltd. | Drug-delivery endovascular stent and method for treating restenosis |
EP1441707A1 (fr) | 2001-11-09 | 2004-08-04 | Pharmacia AB | Agent anti-muscarinique et agoniste des oestrogenes pour traiter une vessie instable ou hyperactive |
US6517889B1 (en) | 2001-11-26 | 2003-02-11 | Swaminathan Jayaraman | Process for coating a surface of a stent |
US7488313B2 (en) * | 2001-11-29 | 2009-02-10 | Boston Scientific Scimed, Inc. | Mechanical apparatus and method for dilating and delivering a therapeutic agent to a site of treatment |
US6868123B2 (en) | 2001-12-07 | 2005-03-15 | Motorola, Inc. | Programmable motion estimation module with vector array unit |
TW497494U (en) | 2001-12-28 | 2002-08-01 | Metal Ind Redearch & Amp Dev C | Fluid driven stirring device for compressing gas cleaning system |
DE10200388A1 (de) | 2002-01-08 | 2003-07-24 | Translumina Gmbh | Beschichtungssystem |
CN1615137A (zh) * | 2002-01-10 | 2005-05-11 | 诺瓦提斯公司 | 用于预防和治疗血管疾病、包含雷帕霉素及其衍生物的药物递送系统 |
US20030135256A1 (en) | 2002-01-14 | 2003-07-17 | Gallagher Brendan P. | Stent delivery system |
CN1279984C (zh) * | 2002-02-15 | 2006-10-18 | Cv医药有限公司 | 用于医用装置的聚合物涂层 |
US20060093771A1 (en) * | 2002-02-15 | 2006-05-04 | Frantisek Rypacek | Polymer coating for medical devices |
NZ534544A (en) | 2002-02-28 | 2007-05-31 | Novartis Ag | N- {5-[4-(4-methyl-piperazino-methyl)-benzoylamido]-2-methylphenyl} -4-(3-pyridyl)-2-pyrimidine-amine coated stents |
AU2003228269A1 (en) | 2002-03-01 | 2003-09-16 | Mds Proteomics Inc. | Phosphorylated proteins and uses related thereto |
GB0205868D0 (en) * | 2002-03-13 | 2002-04-24 | Univ Nottingham | Polymer composite with internally distributed deposition matter |
US7919075B1 (en) | 2002-03-20 | 2011-04-05 | Advanced Cardiovascular Systems, Inc. | Coatings for implantable medical devices |
US6743463B2 (en) | 2002-03-28 | 2004-06-01 | Scimed Life Systems, Inc. | Method for spray-coating a medical device having a tubular wall such as a stent |
US7270675B2 (en) | 2002-05-10 | 2007-09-18 | Cordis Corporation | Method of forming a tubular membrane on a structural frame |
US6669785B2 (en) | 2002-05-15 | 2003-12-30 | Micell Technologies, Inc. | Methods and compositions for etch cleaning microelectronic substrates in carbon dioxide |
US6756084B2 (en) | 2002-05-28 | 2004-06-29 | Battelle Memorial Institute | Electrostatic deposition of particles generated from rapid expansion of supercritical fluid solutions |
US6749902B2 (en) | 2002-05-28 | 2004-06-15 | Battelle Memorial Institute | Methods for producing films using supercritical fluid |
DE60331731D1 (de) | 2002-05-28 | 2010-04-29 | Battelle Memorial Institute | Elektrostatische abscheidung von durch schnelle entspannung überkritischer lösungen (ress) erhaltene partikel |
TW200403065A (en) | 2002-05-30 | 2004-03-01 | Akzo Nobel Nv | New etonogestrel esters |
US7229837B2 (en) | 2002-05-30 | 2007-06-12 | Uchicago Argonne, Llc | Enhanced photophysics of conjugated polymers |
US7638137B2 (en) | 2002-06-05 | 2009-12-29 | University Of Florida Research Foundation, Incorporated | Ophthalmic drug delivery system |
WO2003106543A1 (fr) | 2002-06-13 | 2003-12-24 | Kappler, Inc. | Membrane microporeuse a matiere de remplissage adsorbante et multifonctionnelle |
US6794902B2 (en) | 2002-06-14 | 2004-09-21 | Sun Microsystems, Inc. | Virtual ground circuit |
US7033602B1 (en) | 2002-06-21 | 2006-04-25 | Advanced Cardiovascular Systems, Inc. | Polycationic peptide coatings and methods of coating implantable medical devices |
US7217426B1 (en) | 2002-06-21 | 2007-05-15 | Advanced Cardiovascular Systems, Inc. | Coatings containing polycationic peptides for cardiovascular therapy |
US6839913B2 (en) | 2002-06-25 | 2005-01-11 | Noble Ideas, Inc. | Adjustable garment waistband and method of manufacture |
EP1516597A4 (fr) | 2002-06-27 | 2010-11-10 | Microport Medical Shanghai Co | Stent eluant des medicaments |
CN100471469C (zh) | 2002-06-27 | 2009-03-25 | 微创医疗器械(上海)有限公司 | 一种具有多层涂层的药物洗脱支架 |
US20040013792A1 (en) * | 2002-07-19 | 2004-01-22 | Samuel Epstein | Stent coating holders |
US7491233B1 (en) | 2002-07-19 | 2009-02-17 | Advanced Cardiovascular Systems Inc. | Purified polymers for coatings of implantable medical devices |
JP2004058431A (ja) | 2002-07-29 | 2004-02-26 | Nitto Denko Corp | 粘着テープ又はシート |
GB2391439B (en) | 2002-07-30 | 2006-06-21 | Wolfson Ltd | Bass compressor |
US20050019747A1 (en) | 2002-08-07 | 2005-01-27 | Anderson Daniel G. | Nanoliter-scale synthesis of arrayed biomaterials and screening thereof |
US7029495B2 (en) * | 2002-08-28 | 2006-04-18 | Scimed Life Systems, Inc. | Medical devices and methods of making the same |
US7060051B2 (en) * | 2002-09-24 | 2006-06-13 | Scimed Life Systems, Inc. | Multi-balloon catheter with hydrogel coating |
EP1549253A4 (fr) * | 2002-09-26 | 2010-11-03 | Endovascular Devices Inc | Appareil et procede de distribution de mitomycine au moyen d'un dispositif medical d'elution biocompatible implantable |
US6770729B2 (en) | 2002-09-30 | 2004-08-03 | Medtronic Minimed, Inc. | Polymer compositions containing bioactive agents and methods for their use |
US6702850B1 (en) | 2002-09-30 | 2004-03-09 | Mediplex Corporation Korea | Multi-coated drug-eluting stent for antithrombosis and antirestenosis |
US6800663B2 (en) | 2002-10-18 | 2004-10-05 | Alkermes Controlled Therapeutics Inc. Ii, | Crosslinked hydrogel copolymers |
KR100511030B1 (ko) | 2002-10-21 | 2005-08-31 | 한국과학기술연구원 | 혈액적합성 의료용 금속 재료 및 이의 제조 방법 |
US7462593B2 (en) | 2002-11-07 | 2008-12-09 | Us Gov Health & Human Serv | Compositions and methods for promoting angiogenesis |
US20050070989A1 (en) | 2002-11-13 | 2005-03-31 | Whye-Kei Lye | Medical devices having porous layers and methods for making the same |
US20040098106A1 (en) | 2002-11-14 | 2004-05-20 | Williams Michael S. | Intraluminal prostheses and carbon dioxide-assisted methods of impregnating same with pharmacological agents |
EP1567099A4 (fr) | 2002-11-15 | 2011-03-30 | Synecor Llc | Endoprotheses ameliorees et procedes de fabrication |
JP4987232B2 (ja) * | 2002-11-18 | 2012-07-25 | ラットガーズ,ザ・ステート・ユニバーシティ・オブ・ニュージャージー | 新規のポリマーを用いた医療用デバイス |
JP4371653B2 (ja) | 2002-11-25 | 2009-11-25 | テルモ株式会社 | 体内埋込医療器具 |
US6790483B2 (en) | 2002-12-06 | 2004-09-14 | Eastman Kodak Company | Method for producing patterned deposition from compressed fluid |
US7094256B1 (en) | 2002-12-16 | 2006-08-22 | Advanced Cardiovascular Systems, Inc. | Coatings for implantable medical device containing polycationic peptides |
WO2004060059A2 (fr) | 2002-12-23 | 2004-07-22 | Vical Incorporated | Procede de lyophilisation de complexes d'acide nucleique/copolymere sequence/tensioactif cationique |
US7152452B2 (en) | 2002-12-26 | 2006-12-26 | Advanced Cardiovascular Systems, Inc. | Assembly for crimping an intraluminal device and method of use |
US20040143317A1 (en) | 2003-01-17 | 2004-07-22 | Stinson Jonathan S. | Medical devices |
US7309349B2 (en) | 2003-01-23 | 2007-12-18 | Cordis Corporation | Friction reducing lubricant for stent loading and stent delivery systems |
JP2004225126A (ja) | 2003-01-24 | 2004-08-12 | Pioneer Electronic Corp | 成膜用マスクとその製造方法 |
US20050079199A1 (en) * | 2003-02-18 | 2005-04-14 | Medtronic, Inc. | Porous coatings for drug release from medical devices |
WO2004075781A2 (fr) | 2003-02-26 | 2004-09-10 | Medivas, Llc | Endoprotheses vasculaires bioactives et leur mode d'emploi |
US20080051866A1 (en) * | 2003-02-26 | 2008-02-28 | Chao Chin Chen | Drug delivery devices and methods |
US7871607B2 (en) | 2003-03-05 | 2011-01-18 | Halozyme, Inc. | Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminoglycanases |
US7527632B2 (en) | 2003-03-31 | 2009-05-05 | Cordis Corporation | Modified delivery device for coated medical devices |
US7326734B2 (en) * | 2003-04-01 | 2008-02-05 | The Regents Of The University Of California | Treatment of bladder and urinary tract cancers |
WO2004091571A2 (fr) | 2003-04-08 | 2004-10-28 | New Jersey Institute Of Technology (Njit) | Revetement/enrobage de nanoparticules au moyen de polymeres par un procede par antisolvant supercritique |
US20060102871A1 (en) | 2003-04-08 | 2006-05-18 | Xingwu Wang | Novel composition |
US20050216075A1 (en) | 2003-04-08 | 2005-09-29 | Xingwu Wang | Materials and devices of enhanced electromagnetic transparency |
US20050208102A1 (en) | 2003-04-09 | 2005-09-22 | Schultz Clyde L | Hydrogels used to deliver medicaments to the eye for the treatment of posterior segment diseases |
US20050038498A1 (en) * | 2003-04-17 | 2005-02-17 | Nanosys, Inc. | Medical device applications of nanostructured surfaces |
US8246974B2 (en) | 2003-05-02 | 2012-08-21 | Surmodics, Inc. | Medical devices and methods for producing the same |
GB0310300D0 (en) | 2003-05-06 | 2003-06-11 | Univ Belfast | Nanocomposite drug delivery composition |
US7279174B2 (en) | 2003-05-08 | 2007-10-09 | Advanced Cardiovascular Systems, Inc. | Stent coatings comprising hydrophilic additives |
US7429378B2 (en) | 2003-05-13 | 2008-09-30 | Depuy Spine, Inc. | Transdiscal administration of high affinity anti-MMP inhibitors |
US7553827B2 (en) | 2003-08-13 | 2009-06-30 | Depuy Spine, Inc. | Transdiscal administration of cycline compounds |
JP2007504920A (ja) | 2003-05-16 | 2007-03-08 | ブルー メンブレーンス ゲーエムベーハー | 生体適合性コーティングされた医療用インプラント |
US7524527B2 (en) | 2003-05-19 | 2009-04-28 | Boston Scientific Scimed, Inc. | Electrostatic coating of a device |
US20040236416A1 (en) | 2003-05-20 | 2004-11-25 | Robert Falotico | Increased biocompatibility of implantable medical devices |
US7662864B2 (en) * | 2003-06-04 | 2010-02-16 | Rutgers, The State University Of New Jersey | Solution polymerization processes to prepare a polymer that degrades to release a physiologically active agent |
WO2004108274A1 (fr) | 2003-06-06 | 2004-12-16 | Mitsubishi Chemical Corporation | Articles absorbant l'eau et procede de production de ces derniers |
WO2004113429A2 (fr) | 2003-06-23 | 2004-12-29 | The University Of Chicago | Nanocomposites polyoléfiniques |
US8399013B2 (en) | 2003-06-26 | 2013-03-19 | Poly-Med, Inc. | Partially absorbable fiber-reinforced composites for controlled drug delivery |
US7318945B2 (en) * | 2003-07-09 | 2008-01-15 | Medtronic Vascular, Inc. | Laminated drug-polymer coated stent having dipped layers |
US8025637B2 (en) * | 2003-07-18 | 2011-09-27 | Boston Scientific Scimed, Inc. | Medical balloons and processes for preparing same |
US7128277B2 (en) | 2003-07-29 | 2006-10-31 | Illinois Tool Works Inc. | Powder bell with secondary charging electrode |
US7056591B1 (en) | 2003-07-30 | 2006-06-06 | Advanced Cardiovascular Systems, Inc. | Hydrophobic biologically absorbable coatings for drug delivery devices and methods for fabricating the same |
US7169404B2 (en) * | 2003-07-30 | 2007-01-30 | Advanced Cardiovasular Systems, Inc. | Biologically absorbable coatings for implantable devices and methods for fabricating the same |
US20050033417A1 (en) * | 2003-07-31 | 2005-02-10 | John Borges | Coating for controlled release of a therapeutic agent |
WO2005011796A1 (fr) | 2003-08-05 | 2005-02-10 | Kaneka Corporation | Stent a mettre en place in vivo |
AP1899A (en) | 2003-08-08 | 2008-10-10 | Biovail Lab Int Srl | Modified-release tablet of bupropion hydrochloride |
EP1684820A2 (fr) * | 2003-08-13 | 2006-08-02 | Medtronic, Inc. | Systemes de distribution d'agents actifs comprenant un melange de polymeres miscibles, dispositifs medicaux et procedes |
US7204560B2 (en) | 2003-08-15 | 2007-04-17 | Sandvik Intellectual Property Ab | Rotary cutting bit with material-deflecting ledge |
EP1656165B1 (fr) | 2003-08-19 | 2008-12-17 | PolyBioMed Limited | Systeme polymere de liberation de medicament pour dispositifs medicaux |
US7785653B2 (en) | 2003-09-22 | 2010-08-31 | Innovational Holdings Llc | Method and apparatus for loading a beneficial agent into an expandable medical device |
US8801692B2 (en) | 2003-09-24 | 2014-08-12 | Medtronic Vascular, Inc. | Gradient coated stent and method of fabrication |
US20050070990A1 (en) * | 2003-09-26 | 2005-03-31 | Stinson Jonathan S. | Medical devices and methods of making same |
US7744645B2 (en) | 2003-09-29 | 2010-06-29 | Medtronic Vascular, Inc. | Laminated drug-polymer coated stent with dipped and cured layers |
US7618647B2 (en) | 2003-10-03 | 2009-11-17 | Boston Scientific Scimed, Inc. | Using bucky paper as a therapeutic aid in medical applications |
US6984411B2 (en) | 2003-10-14 | 2006-01-10 | Boston Scientific Scimed, Inc. | Method for roll coating multiple stents |
US7329383B2 (en) | 2003-10-22 | 2008-02-12 | Boston Scientific Scimed, Inc. | Alloy compositions and devices including the compositions |
JP2007509220A (ja) | 2003-10-23 | 2007-04-12 | ユニバーシテイ・オブ・ノツテインガム | 活性ポリマー押出物の調製 |
US7220755B2 (en) | 2003-11-12 | 2007-05-22 | Biosensors International Group, Ltd. | 42-O-alkoxyalkyl rapamycin derivatives and compositions comprising same |
JP4618997B2 (ja) | 2003-12-09 | 2011-01-26 | テルモ株式会社 | ステントおよびその製造方法 |
DE602004009829T2 (de) | 2003-12-16 | 2008-08-21 | Cytec Surface Specialties, S.A. | Verfahren zum aufbringen einer beschichtung auf ein gewickeltes metallblech |
US20050131513A1 (en) | 2003-12-16 | 2005-06-16 | Cook Incorporated | Stent catheter with a permanently affixed conductor |
PT1699503E (pt) | 2003-12-24 | 2012-06-06 | Novartis Ag | Dispositivos revestidos com polímeros do tipo pec |
US20050147734A1 (en) | 2004-01-07 | 2005-07-07 | Jan Seppala | Method and system for coating tubular medical devices |
US20050268573A1 (en) | 2004-01-20 | 2005-12-08 | Avantec Vascular Corporation | Package of sensitive articles |
US7306677B2 (en) | 2004-01-30 | 2007-12-11 | Boston Scientific Corporation | Clamping fixture for coating stents, system using the fixture, and method of using the fixture |
GB2411078B (en) | 2004-02-10 | 2009-02-04 | Samsung Electronics Co Ltd | Mobile communications |
US7241344B2 (en) | 2004-02-10 | 2007-07-10 | Boston Scientific Scimed, Inc. | Apparatus and method for electrostatic spray coating of medical devices |
US8551512B2 (en) | 2004-03-22 | 2013-10-08 | Advanced Cardiovascular Systems, Inc. | Polyethylene glycol/poly(butylene terephthalate) copolymer coated devices including EVEROLIMUS |
CA2560507C (fr) | 2004-03-26 | 2011-08-16 | Surmodics, Inc. | Composition et procede permettant de preparer des surfaces biocompatibles |
US20050244459A1 (en) | 2004-04-06 | 2005-11-03 | Dewitt David M | Coating compositions for bioactive agents |
US7335264B2 (en) | 2004-04-22 | 2008-02-26 | Boston Scientific Scimed, Inc. | Differentially coated medical devices, system for differentially coating medical devices, and coating method |
US20050288481A1 (en) | 2004-04-30 | 2005-12-29 | Desnoyer Jessica R | Design of poly(ester amides) for the control of agent-release from polymeric compositions |
US7820732B2 (en) | 2004-04-30 | 2010-10-26 | Advanced Cardiovascular Systems, Inc. | Methods for modulating thermal and mechanical properties of coatings on implantable devices |
WO2005117942A2 (fr) | 2004-05-14 | 2005-12-15 | The Regents Of The University Of Michigan | Procedes d'encapsulation de biomacromolecules dans des polymeres |
WO2006085898A1 (fr) | 2004-05-14 | 2006-08-17 | Becton, Dickinson & Company | Articles presentant des surfaces bioactives et procedes de preparation desdits articles sans solvant |
US7682656B2 (en) | 2004-06-14 | 2010-03-23 | Agruim Inc. | Process and apparatus for producing a coated product |
US7976557B2 (en) | 2004-06-23 | 2011-07-12 | Boston Scientific Scimed, Inc. | Cutting balloon and process |
US20060001011A1 (en) * | 2004-07-02 | 2006-01-05 | Wilson Neil R | Surface conditioner for powder coating systems |
WO2006019904A1 (fr) | 2004-07-14 | 2006-02-23 | University Of Utha Research Foundation | Compositions et utilisations liées à des nétrines |
US8541078B2 (en) * | 2004-08-06 | 2013-09-24 | Societe Bic | Fuel supplies for fuel cells |
US20060104969A1 (en) | 2004-08-16 | 2006-05-18 | Massachusetts Institute Of Technology | Compositions and methods for enhancing structural and functional nervous system reorganization and recovery |
US7425368B2 (en) | 2004-08-20 | 2008-09-16 | Massachusetts Institute Of Technology | Filler-enhanced polymeric fibers with improved mechanical properties and method for making |
US8119153B2 (en) | 2004-08-26 | 2012-02-21 | Boston Scientific Scimed, Inc. | Stents with drug eluting coatings |
JP4894519B2 (ja) | 2004-09-08 | 2012-03-14 | 株式会社カネカ | 生体留置用ステント |
JP5056013B2 (ja) | 2004-09-08 | 2012-10-24 | 株式会社カネカ | 生体留置用ステント |
WO2006036982A2 (fr) | 2004-09-28 | 2006-04-06 | Atrium Medical Corporation | Revetement d'administration de medicament pouvant etre utilise avec une endoprothese vasculaire |
AU2005292339A1 (en) * | 2004-09-29 | 2006-04-13 | Cordis Corporation | Pharmaceutical dosage forms of stable amorphous rapamycin like compounds |
US8313763B2 (en) | 2004-10-04 | 2012-11-20 | Tolmar Therapeutics, Inc. | Sustained delivery formulations of rapamycin compounds |
US20060093643A1 (en) | 2004-11-04 | 2006-05-04 | Stenzel Eric B | Medical device for delivering therapeutic agents over different time periods |
US7455658B2 (en) | 2004-11-10 | 2008-11-25 | Samw Hong Jen Wang | Fluid dispensing or feeding device |
US7455688B2 (en) | 2004-11-12 | 2008-11-25 | Con Interventional Systems, Inc. | Ostial stent |
WO2006063021A2 (fr) | 2004-12-07 | 2006-06-15 | Surmodics, Inc. | Revetements comprenant un ou plusieurs agents actifs cristallises et methodes associees |
US20070059350A1 (en) * | 2004-12-13 | 2007-03-15 | Kennedy John P | Agents for controlling biological fluids and methods of use thereof |
US7632307B2 (en) | 2004-12-16 | 2009-12-15 | Advanced Cardiovascular Systems, Inc. | Abluminal, multilayer coating constructs for drug-delivery stents |
US20060198868A1 (en) | 2005-01-05 | 2006-09-07 | Dewitt David M | Biodegradable coating compositions comprising blends |
US7727273B2 (en) | 2005-01-13 | 2010-06-01 | Boston Scientific Scimed, Inc. | Medical devices and methods of making the same |
US7772352B2 (en) | 2005-01-28 | 2010-08-10 | Bezwada Biomedical Llc | Bioabsorbable and biocompatible polyurethanes and polyamides for medical devices |
WO2006110197A2 (fr) * | 2005-03-03 | 2006-10-19 | Icon Medical Corp. | Dispositif medical en polymere biodegradable |
US7837726B2 (en) * | 2005-03-14 | 2010-11-23 | Abbott Laboratories | Visible endoprosthesis |
WO2006099276A2 (fr) | 2005-03-14 | 2006-09-21 | 3M Innovative Properties Company | Composes de polymeres biocompatibles pour preparations medicales |
EA200701998A1 (ru) | 2005-03-17 | 2008-02-28 | Элан Фарма Интернэшнл Лтд. | Композиции для инъекций наночастиц иммунодепрессивных соединений |
EP1868663B1 (fr) | 2005-03-23 | 2011-11-16 | Abbott Laboratories | Distribution d'agents hautement lipophiles au moyen de dispositifs medicaux |
US8628565B2 (en) | 2005-04-13 | 2014-01-14 | Abbott Cardiovascular Systems Inc. | Intravascular stent |
US20070009564A1 (en) | 2005-06-22 | 2007-01-11 | Mcclain James B | Drug/polymer composite materials and methods of making the same |
WO2007011708A2 (fr) | 2005-07-15 | 2007-01-25 | Micell Technologies, Inc. | Stent a revetement polymere renfermant de la rapamycine amorphe |
US8298565B2 (en) | 2005-07-15 | 2012-10-30 | Micell Technologies, Inc. | Polymer coatings containing drug powder of controlled morphology |
US20070026042A1 (en) | 2005-07-29 | 2007-02-01 | Narayanan Pallasssana V | System for treating aneurysmal disease |
US8377462B2 (en) | 2005-07-29 | 2013-02-19 | Advanced Cardiovascular Systems, Inc. | PEA-TEMPO/PEA-BZ coatings for controlled delivery of drug from implantable medical devices |
US7862848B2 (en) | 2005-08-03 | 2011-01-04 | The University Of Western Ontario | Direct coating solid dosage forms using powdered materials |
EP1911214B1 (fr) | 2005-08-05 | 2008-12-10 | Telecom Italia S.p.A. | Procédé d'établissement d'une connexion sur un réseau de communication |
WO2007017707A1 (fr) | 2005-08-11 | 2007-02-15 | Hilary Nwokeabia | Brosse a dents a poils en pente |
WO2007022055A1 (fr) | 2005-08-12 | 2007-02-22 | Massicotte J Mathieu | Procede et dispositif d'extraction d'objets du corps |
US20070043434A1 (en) | 2005-08-18 | 2007-02-22 | David Meerkin | Biodegradable endovascular stent using stereocomplexation of polymers |
EP1764116A1 (fr) | 2005-09-16 | 2007-03-21 | Debiotech S.A. | Production d'un revêtement poreux à l'aide des particules colloidales |
US7935379B2 (en) * | 2005-11-14 | 2011-05-03 | Boston Scientific Scimed, Inc. | Coated and imprinted medical devices and methods of making the same |
US20070196423A1 (en) | 2005-11-21 | 2007-08-23 | Med Institute, Inc. | Implantable medical device coatings with biodegradable elastomer and releasable therapeutic agent |
DK1957130T3 (da) | 2005-12-09 | 2010-11-22 | Dsm Ip Assets Bv | Hydrofilt overtræk omfattende en polyelektrolyt |
US20070148251A1 (en) | 2005-12-22 | 2007-06-28 | Hossainy Syed F A | Nanoparticle releasing medical devices |
US7842312B2 (en) | 2005-12-29 | 2010-11-30 | Cordis Corporation | Polymeric compositions comprising therapeutic agents in crystalline phases, and methods of forming the same |
US8834912B2 (en) * | 2005-12-30 | 2014-09-16 | Boston Scientific Scimed, Inc. | Medical devices having multiple charged layers |
US20080286325A1 (en) | 2006-01-05 | 2008-11-20 | Med Institute, Inc. | Cyclodextrin elution media for medical device coatings comprising a taxane therapeutic agent |
US7919108B2 (en) | 2006-03-10 | 2011-04-05 | Cook Incorporated | Taxane coatings for implantable medical devices |
JP5128497B2 (ja) | 2006-01-23 | 2013-01-23 | スミス アンド ネフュー インコーポレーテッド | 膝蓋構成要素 |
US20070299518A1 (en) | 2006-01-27 | 2007-12-27 | Med Institute, Inc. | Device with nanocomposite coating for controlled drug release |
WO2007089259A1 (fr) | 2006-02-02 | 2007-08-09 | The Johns Hopkins University | Compositions therapeutiques de fibres electrofilees |
US20070196242A1 (en) | 2006-02-23 | 2007-08-23 | Agamatrix, Inc. | Used test strip storage container |
US20070200268A1 (en) | 2006-02-24 | 2007-08-30 | Vipul Dave | Implantable device prepared from solution processing |
US20070203569A1 (en) | 2006-02-24 | 2007-08-30 | Robert Burgermeister | Implantable device formed from polymer blends having modified molecular structures |
US8500772B2 (en) | 2006-03-20 | 2013-08-06 | Cook Medical Technologies Llc | Distal protection device |
US20070225795A1 (en) | 2006-03-24 | 2007-09-27 | Juan Granada | Composite vascular prosthesis |
US7955383B2 (en) * | 2006-04-25 | 2011-06-07 | Medtronics Vascular, Inc. | Laminated implantable medical device having a metallic coating |
PL2019657T3 (pl) | 2006-04-26 | 2015-10-30 | Micell Technologies Inc | Powłoki zawierające wiele leków |
US7691400B2 (en) | 2006-05-05 | 2010-04-06 | Medtronic Vascular, Inc. | Medical device having coating with zeolite drug reservoirs |
US20080279909A1 (en) | 2006-05-12 | 2008-11-13 | Cleek Robert L | Immobilized Biologically Active Entities Having A High Degree of Biological Activity Following Sterilization |
US7959940B2 (en) | 2006-05-30 | 2011-06-14 | Advanced Cardiovascular Systems, Inc. | Polymer-bioceramic composite implantable medical devices |
US20070281117A1 (en) | 2006-06-02 | 2007-12-06 | Xtent, Inc. | Use of plasma in formation of biodegradable stent coating |
US20080124372A1 (en) * | 2006-06-06 | 2008-05-29 | Hossainy Syed F A | Morphology profiles for control of agent release rates from polymer matrices |
BRPI0603437A2 (pt) | 2006-06-06 | 2010-07-06 | Luiz Gonzaga Granja Jr | prótese para anastomose tipo stent extraluminal |
US8535372B1 (en) * | 2006-06-16 | 2013-09-17 | Abbott Cardiovascular Systems Inc. | Bioabsorbable stent with prohealing layer |
WO2008008291A2 (fr) | 2006-07-13 | 2008-01-17 | Icon Medical Corp. | Stent |
US7812032B2 (en) | 2006-07-25 | 2010-10-12 | Abbott Laboratories | Crystalline forms of rapamycin analogs |
CN104906087A (zh) | 2006-09-13 | 2015-09-16 | 万能医药公司 | 大环内酯化合物及它们的使用方法 |
US20080065192A1 (en) | 2006-09-13 | 2008-03-13 | Medtronic Vascular, Inc. | Compliance Graded Stent |
US9402936B2 (en) | 2006-09-15 | 2016-08-02 | Boston Scientific Scimed, Inc. | Medical devices having alloy compositions |
WO2008036554A2 (fr) | 2006-09-18 | 2008-03-27 | Boston Scientific Limited | Endoprosthèses |
WO2008039749A2 (fr) * | 2006-09-25 | 2008-04-03 | Surmodics, Inc. | Revêtements multicouches, et procédés pour contrôler une élution d'éléments actif |
US8636767B2 (en) * | 2006-10-02 | 2014-01-28 | Micell Technologies, Inc. | Surgical sutures having increased strength |
EP1916006A1 (fr) | 2006-10-19 | 2008-04-30 | Albert Schömig | Implant revêtu de cire ou de résine |
EP1913960A1 (fr) | 2006-10-19 | 2008-04-23 | Albert Schömig | implant enrobé |
US7959942B2 (en) * | 2006-10-20 | 2011-06-14 | Orbusneich Medical, Inc. | Bioabsorbable medical device with coating |
US20080097591A1 (en) * | 2006-10-20 | 2008-04-24 | Biosensors International Group | Drug-delivery endovascular stent and method of use |
CN101678388B (zh) | 2006-10-23 | 2013-12-11 | 米歇尔技术公司 | 用于在涂覆过程中为基底充电的保持器 |
US20080098178A1 (en) | 2006-10-23 | 2008-04-24 | Veazey Judson E | Data storage on a switching system coupling multiple processors of a computer system |
US7981150B2 (en) | 2006-11-09 | 2011-07-19 | Boston Scientific Scimed, Inc. | Endoprosthesis with coatings |
US8425459B2 (en) | 2006-11-20 | 2013-04-23 | Lutonix, Inc. | Medical device rapid drug releasing coatings comprising a therapeutic agent and a contrast agent |
US8430055B2 (en) | 2008-08-29 | 2013-04-30 | Lutonix, Inc. | Methods and apparatuses for coating balloon catheters |
US20080175887A1 (en) | 2006-11-20 | 2008-07-24 | Lixiao Wang | Treatment of Asthma and Chronic Obstructive Pulmonary Disease With Anti-proliferate and Anti-inflammatory Drugs |
WO2008070996A1 (fr) | 2006-12-13 | 2008-06-19 | Angiotech Pharmaceuticals Inc. | Implants médicaux avec une combinaison de paclitaxel et de dipyridamole |
US8114466B2 (en) | 2007-01-03 | 2012-02-14 | Boston Scientific Scimed, Inc. | Methods of applying coating to the inside surface of a stent |
CA2679712C (fr) | 2007-01-08 | 2016-11-15 | Micell Technologies, Inc. | Stents comportant des couches biodegradables |
US20130150943A1 (en) | 2007-01-19 | 2013-06-13 | Elixir Medical Corporation | Biodegradable endoprostheses and methods for their fabrication |
US7745566B2 (en) | 2007-01-23 | 2010-06-29 | Ferro Corporation | Methods for the purification of polymers |
US7887830B2 (en) | 2007-02-27 | 2011-02-15 | Boston Scientific Scimed, Inc. | Medical devices having polymeric regions based on styrene-isobutylene copolymers |
US8401258B2 (en) | 2007-03-16 | 2013-03-19 | Sti Medical Systems, Llc | Method to provide automated quality feedback to imaging devices to achieve standardized imaging data |
US7815962B2 (en) | 2007-03-22 | 2010-10-19 | Medtronic Vascular, Inc. | Coated stent with evenly distributed therapeutic agent |
WO2008124634A1 (fr) | 2007-04-04 | 2008-10-16 | Massachusetts Institute Of Technology | Micelles inverses encapsulées par un polymère |
US9433516B2 (en) | 2007-04-17 | 2016-09-06 | Micell Technologies, Inc. | Stents having controlled elution |
AU2008242844A1 (en) | 2007-04-17 | 2008-10-30 | Micell Technologies, Inc. | Stents having biodegradable layers |
WO2008137148A2 (fr) | 2007-05-03 | 2008-11-13 | Abraxis Bioscience, Llc | Procédés et compositions permettant le traitement de l'hypertension pulmonaire |
WO2008144600A1 (fr) | 2007-05-17 | 2008-11-27 | Prescient Medical, Inc. | Systèmes de spectroscopie par fibres optiques multicanal utilisant des modules optiques intégrés |
GB0709517D0 (en) | 2007-05-17 | 2007-06-27 | Queen Mary & Westfield College | An electrostatic spraying device and a method of electrostatic spraying |
EP2170418B1 (fr) | 2007-05-25 | 2016-03-16 | Micell Technologies, Inc. | Films de polymères pour le revêtement des dispositifs médicaux |
US7922760B2 (en) | 2007-05-29 | 2011-04-12 | Abbott Cardiovascular Systems Inc. | In situ trapping and delivery of agent by a stent having trans-strut depots |
US8109904B1 (en) | 2007-06-25 | 2012-02-07 | Abbott Cardiovascular Systems Inc. | Drug delivery medical devices |
US20090068266A1 (en) * | 2007-09-11 | 2009-03-12 | Raheja Praveen | Sirolimus having specific particle size and pharmaceutical compositions thereof |
US9248219B2 (en) | 2007-09-14 | 2016-02-02 | Boston Scientific Scimed, Inc. | Medical devices having bioerodable layers for the release of therapeutic agents |
US20090076446A1 (en) * | 2007-09-14 | 2009-03-19 | Quest Medical, Inc. | Adjustable catheter for dilation in the ear, nose or throat |
WO2009039553A1 (fr) | 2007-09-27 | 2009-04-02 | The Walter And Eliza Hall Institute Of Medical Research | Composés de benzothiazole |
JP5114788B2 (ja) | 2007-09-28 | 2013-01-09 | 三菱重工業株式会社 | リチウム二次電池 |
US8709071B1 (en) | 2007-09-28 | 2014-04-29 | Abbott Cardiovascular Systems Inc. | Stent with preferential coating |
US20090105687A1 (en) | 2007-10-05 | 2009-04-23 | Angioscore, Inc. | Scoring catheter with drug delivery membrane |
HUE055815T2 (hu) | 2007-10-05 | 2021-12-28 | Univ Wayne State | Vegyületek nyújtott felszabadítására alkalmas dendrimerek |
WO2009051607A1 (fr) * | 2007-10-19 | 2009-04-23 | Medlogics Device Corporation | Stents implantables et de soutien de la lumière et procédés associés de fabrication et d'utilisation |
US20100298928A1 (en) | 2007-10-19 | 2010-11-25 | Micell Technologies, Inc. | Drug Coated Stents |
EP2997985A1 (fr) | 2007-10-30 | 2016-03-23 | Nanyang Technological University | Endoprothèse vasculaire non biodégradable comprenant un revêtement biodégradable et procédé de revêtement de celle-ci |
US8642062B2 (en) * | 2007-10-31 | 2014-02-04 | Abbott Cardiovascular Systems Inc. | Implantable device having a slow dissolving polymer |
US20090111787A1 (en) * | 2007-10-31 | 2009-04-30 | Florencia Lim | Polymer blends for drug delivery stent matrix with improved thermal stability |
CN101161300B (zh) | 2007-11-27 | 2011-03-16 | 北京美中双和医疗器械有限公司 | 三氧化二砷药物洗脱支架及其制备方法 |
US20090202609A1 (en) | 2008-01-06 | 2009-08-13 | Keough Steven J | Medical device with coating composition |
US20100042206A1 (en) * | 2008-03-04 | 2010-02-18 | Icon Medical Corp. | Bioabsorbable coatings for medical devices |
US20090227948A1 (en) | 2008-03-06 | 2009-09-10 | Boston Scientific Scimed, Inc. | Balloon catheter devices with sheath covering |
EP2689789B1 (fr) | 2008-03-28 | 2019-03-13 | SurModics, Inc. | Dispositifs médicaux insérables présentant des substrats élastiques associés à des microparticules et procédés d'administration de médicaments |
MX2010011485A (es) | 2008-04-17 | 2011-03-01 | Micell Technologies Inc | Stents que contienen capas bioadsorbibles. |
US8557273B2 (en) | 2008-04-18 | 2013-10-15 | Medtronic, Inc. | Medical devices and methods including polymers having biologically active agents therein |
US20110143429A1 (en) | 2008-04-30 | 2011-06-16 | Iksoo Chun | Tissue engineered blood vessels |
CN102017221B (zh) | 2008-05-08 | 2013-01-02 | 新日铁化学株式会社 | 有机场致发光元件用化合物及有机场致发光元件 |
US8298607B2 (en) | 2008-05-15 | 2012-10-30 | Abbott Cardiovascular Systems Inc. | Method for electrostatic coating of a medical device |
US7865562B2 (en) | 2008-05-20 | 2011-01-04 | International Business Machines Corporation | Selecting email signatures |
EP2131614B1 (fr) | 2008-05-30 | 2014-01-01 | Alcatel Lucent | Procédé de transmission de services de diffusion dans un réseau cellulaire de radiocommunication via une station de base femto, et station de base femto correspondante |
US20090297578A1 (en) | 2008-06-03 | 2009-12-03 | Trollsas Mikael O | Biosoluble coating comprising anti-proliferative and anti-inflammatory agent combination for treatment of vascular disorders |
US20110189299A1 (en) | 2008-07-01 | 2011-08-04 | Nitto Denko Corporation | Pharmaceutical composition containing surface-coated microparticles |
US7770466B2 (en) | 2008-07-02 | 2010-08-10 | Abbott Cardiovascular Systems Inc. | Method for measuring stent dislodgement force |
JP4557061B2 (ja) | 2008-07-11 | 2010-10-06 | トヨタ自動車株式会社 | ハイブリッド自動車およびその制御方法 |
US9510856B2 (en) | 2008-07-17 | 2016-12-06 | Micell Technologies, Inc. | Drug delivery medical device |
AU2009270849B2 (en) * | 2008-07-17 | 2013-11-21 | Micell Technologies, Inc. | Drug delivery medical device |
JP2010052503A (ja) | 2008-08-27 | 2010-03-11 | Kawano Terukazu | 船舶用エンジン |
US20100055145A1 (en) | 2008-08-29 | 2010-03-04 | Biosensors International Group | Stent coatings for reducing late stent thrombosis |
US8367090B2 (en) * | 2008-09-05 | 2013-02-05 | Abbott Cardiovascular Systems Inc. | Coating on a balloon comprising a polymer and a drug |
AU2009293445A1 (en) | 2008-09-19 | 2010-03-25 | Innovative Surface Technologies, Inc. | Drug eluting superhydrophobic coatings |
EP2328523A2 (fr) | 2008-09-29 | 2011-06-08 | Robert Ndondo-Lay | Stent revêtu d'une matrice |
US8535655B2 (en) | 2008-10-10 | 2013-09-17 | Polyactiva Pty Ltd. | Biodegradable polymer—bioactive moiety conjugates |
US20120064143A1 (en) | 2008-11-11 | 2012-03-15 | The Board Of Regents Of The University Of Texas System | Inhibition of mammalian target of rapamycin |
US8333803B2 (en) | 2008-11-21 | 2012-12-18 | Lifecell Corporation | Reinforced biologic material |
EP2384206B1 (fr) | 2008-12-26 | 2018-08-01 | Battelle Memorial Institute | Implants médicaux et procédés de fabrication associés |
US8834913B2 (en) | 2008-12-26 | 2014-09-16 | Battelle Memorial Institute | Medical implants and methods of making medical implants |
US9572692B2 (en) | 2009-02-02 | 2017-02-21 | Abbott Cardiovascular Systems Inc. | Bioabsorbable stent that modulates plaque geometric morphology and chemical composition |
WO2010086863A2 (fr) | 2009-02-02 | 2010-08-05 | Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. | Revêtements contenant un médicament cristallin |
US20100198330A1 (en) | 2009-02-02 | 2010-08-05 | Hossainy Syed F A | Bioabsorbable Stent And Treatment That Elicits Time-Varying Host-Material Response |
EP2410954A4 (fr) | 2009-03-23 | 2014-03-05 | Micell Technologies Inc | Endoprothèses périphériques dotées de couches |
EP2411440B1 (fr) | 2009-03-23 | 2018-01-17 | Micell Technologies, Inc. | Polymères biodégradables améliorés |
WO2010111232A2 (fr) | 2009-03-23 | 2010-09-30 | Micell Technologies, Inc. | Dispositif médical d'administration de médicament |
JP2012522589A (ja) | 2009-04-01 | 2012-09-27 | ミシェル テクノロジーズ,インコーポレイテッド | 被覆ステント |
US20110301697A1 (en) | 2009-04-10 | 2011-12-08 | Hemoteq Ag | Manufacture, method and use of drug-eluting medical devices for permanently keeping blood vessels open |
US9492587B2 (en) | 2009-04-13 | 2016-11-15 | Abbott Cardiovascular Systems Inc. | Stent made from an ultra high molecular weight bioabsorbable polymer with high fatigue and fracture resistance |
US20100285085A1 (en) | 2009-05-07 | 2010-11-11 | Abbott Cardiovascular Systems Inc. | Balloon coating with drug transfer control via coating thickness |
WO2010135369A1 (fr) | 2009-05-18 | 2010-11-25 | Dose Medical Corporation | Implant oculaire à élution de médicament |
WO2010136604A1 (fr) | 2009-05-29 | 2010-12-02 | Dsm Ip Assets B.V. | Matrice de transfert pour le transfert d'un agent bioactif sur un tissu corporel |
EP2266507B1 (fr) | 2009-06-22 | 2015-07-29 | Biotronik VI Patent AG | Stent ayant un design amélioré |
US9327060B2 (en) * | 2009-07-09 | 2016-05-03 | CARDINAL HEALTH SWITZERLAND 515 GmbH | Rapamycin reservoir eluting stent |
US8039147B2 (en) | 2009-08-27 | 2011-10-18 | Sb Limotive Co., Ltd. | Rechargeable secondary battery having improved safety against puncture and collapse |
EP2531140B1 (fr) | 2010-02-02 | 2017-11-01 | Micell Technologies, Inc. | Endoprothèse et système de pose d'endoprothèse avec une capacité améliorée de pose |
CN102883753B (zh) | 2010-03-25 | 2015-04-15 | 路通医疗股份有限公司 | 用于医疗设备的释药涂层 |
US8795762B2 (en) | 2010-03-26 | 2014-08-05 | Battelle Memorial Institute | System and method for enhanced electrostatic deposition and surface coatings |
WO2011123798A2 (fr) | 2010-04-01 | 2011-10-06 | The Johns Hopkins University | Renforts tridimensionnels, procédés pour les façonner et procédés de traitement d'une lésion des nerfs périphériques ou de la moelle épinière |
CA2794704C (fr) | 2010-04-16 | 2019-09-17 | Micell Technologies, Inc. | Endoprotheses vasculaires ayant une elution controlee |
EP2560576B1 (fr) | 2010-04-22 | 2018-07-18 | Micell Technologies, Inc. | Endoprothèses et autres dispositifs ayant un revêtement de matrice extracellulaire |
WO2011140519A2 (fr) | 2010-05-07 | 2011-11-10 | Medicus Biosciences, Llc | Préformulation pharmaceutique se gélifiant in vivo |
EP2593039B1 (fr) | 2010-07-16 | 2022-11-30 | Micell Technologies, Inc. | Dispositif médical d'administration de médicament |
CA2810842C (fr) * | 2010-09-09 | 2018-06-26 | Micell Technologies, Inc. | Formes pharmaceutiques de type macrolides |
WO2012078955A1 (fr) | 2010-12-10 | 2012-06-14 | Micropen Technologies Corporation | Endoprothèses et procédés de fabrication d'endoprothèses |
US8974622B2 (en) | 2010-12-28 | 2015-03-10 | Boston Scientific Scimed, Inc. | Composite ePTFE-silicone covering for stent |
CA2823355C (fr) | 2010-12-30 | 2017-08-22 | Micell Technologies, Inc. | Nanoparticules et revetements particulaires modifies en surface, ballonnets revetus et procedes associes |
WO2012097381A1 (fr) | 2011-01-14 | 2012-07-19 | Biomerix Corporation | Éléments matriciels élastomères réticulés au moins partiellement résorbables et leurs procédés de fabrication |
EP2696815B1 (fr) | 2011-04-13 | 2019-03-20 | Micell Technologies, Inc. | Endoprothèses présentant une élution régulée |
US20120280432A1 (en) | 2011-05-06 | 2012-11-08 | Industrial Technology Research Institute | Method for manufacturing bioabsorbable stents |
US9446172B2 (en) | 2011-05-10 | 2016-09-20 | Abbott Cardiovascular Systems Inc. | Modification of bioabsorbable stent to reduce thrombogenecity |
WO2012166819A1 (fr) | 2011-05-31 | 2012-12-06 | Micell Technologies, Inc. | Système et procédé de formation de revêtement transférable à élution de médicament, libéré dans le temps |
CA2841360A1 (fr) | 2011-07-15 | 2013-01-24 | Micell Technologies, Inc. | Dispositif medical d'administration de medicament |
US20140257465A1 (en) | 2011-08-12 | 2014-09-11 | Micell Technologies, Inc. | Stents having controlled elution |
US10188772B2 (en) | 2011-10-18 | 2019-01-29 | Micell Technologies, Inc. | Drug delivery medical device |
EP2768571B1 (fr) | 2011-10-18 | 2023-02-22 | Micell Technologies, Inc. | Dispositif médical d'administration de médicament |
WO2013177211A1 (fr) | 2012-05-21 | 2013-11-28 | Micell Technologies, Inc. | Endoprothèse à élution de médicament sûre dotée d'un enrobage absorbable |
JP2013153822A (ja) | 2012-01-27 | 2013-08-15 | Terumo Corp | 生体内留置用ステントおよび生体器官拡張器具 |
US9090029B2 (en) | 2012-02-06 | 2015-07-28 | Warsaw Orthopedic, Inc. | Pultrusion process for preparing composites having low percentage of fibers and articles made from same |
US8859088B2 (en) | 2012-04-16 | 2014-10-14 | Auburn University | Minimal weight composites using open structure |
US20150087671A1 (en) | 2012-05-16 | 2015-03-26 | Micell Technologies, Inc. | Low burst sustained release lipophilic and biologic agent compositions |
AU2013331003B2 (en) | 2012-10-18 | 2016-11-24 | Micell Technologies, Inc. | Drug delivery medical device |
CN110269959A (zh) | 2013-03-12 | 2019-09-24 | 脉胜医疗技术公司 | 可生物吸收的生物医学植入物 |
CA2912387C (fr) | 2013-05-15 | 2019-04-16 | Micell Technologies, Inc. | Implants biomedicaux bioabsorbables |
-
2008
- 2008-01-08 CA CA2679712A patent/CA2679712C/fr not_active Expired - Fee Related
- 2008-01-08 US US12/522,379 patent/US9737642B2/en active Active
- 2008-01-08 JP JP2009545647A patent/JP5603598B2/ja active Active
- 2008-01-08 WO PCT/US2008/050536 patent/WO2008086369A1/fr active Application Filing
- 2008-01-08 CN CN200880007308.1A patent/CN101711137B/zh active Active
- 2008-01-08 EP EP08705772.5A patent/EP2111184B1/fr active Active
-
2013
- 2013-09-13 JP JP2013190903A patent/JP2014012218A/ja active Pending
-
2017
- 2017-06-27 US US15/634,246 patent/US10617795B2/en active Active
Patent Citations (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4733665B1 (en) | 1985-11-07 | 1994-01-11 | Expandable Grafts Partnership | Expandable intraluminal graft,and method and apparatus for implanting an expandable intraluminal graft |
US4733665C2 (en) | 1985-11-07 | 2002-01-29 | Expandable Grafts Partnership | Expandable intraluminal graft and method and apparatus for implanting an expandable intraluminal graft |
US4733665A (en) | 1985-11-07 | 1988-03-29 | Expandable Grafts Partnership | Expandable intraluminal graft, and method and apparatus for implanting an expandable intraluminal graft |
US20020091433A1 (en) * | 1995-04-19 | 2002-07-11 | Ni Ding | Drug release coated stent |
US6497729B1 (en) | 1998-11-20 | 2002-12-24 | The University Of Connecticut | Implant coating for control of tissue/implant interactions |
US20040106982A1 (en) * | 1999-03-16 | 2004-06-03 | Jalisi Marc M. | Multilayer stent |
US6838528B2 (en) | 2001-01-19 | 2005-01-04 | Nektar Therapeutics Al, Corporation | Multi-arm block copolymers as drug delivery vehicles |
US6897205B2 (en) | 2001-01-31 | 2005-05-24 | Roehm Gmbh & Co. Kg | Multi-particulate form of medicament, comprising at least two differently coated forms of pellet |
US20030204238A1 (en) * | 2002-04-26 | 2003-10-30 | Eugene Tedeschi | Coated stent with crimpable coating |
US20030222017A1 (en) | 2002-05-28 | 2003-12-04 | Battelle Memorial Institute | Electrostatic deposition of particles generated from rapid expansion of supercritical fluid solutions |
US20050010275A1 (en) * | 2002-10-11 | 2005-01-13 | Sahatjian Ronald A. | Implantable medical devices |
US20060193890A1 (en) * | 2002-11-13 | 2006-08-31 | Owens Gary K | Method for loading nanoporous layers with therapeutic agent |
US20040193262A1 (en) * | 2003-03-29 | 2004-09-30 | Shadduck John H. | Implants for treating ocular hypertension, methods of use and methods of fabrication |
US20050049694A1 (en) * | 2003-08-07 | 2005-03-03 | Medtronic Ave. | Extrusion process for coating stents |
US20050177223A1 (en) * | 2003-09-18 | 2005-08-11 | Palmaz Julio C. | Medical devices having MEMs functionality and methods of making same |
US20050069630A1 (en) * | 2003-09-30 | 2005-03-31 | Advanced Cardiovascular Systems, Inc. | Stent mandrel fixture and method for selectively coating surfaces of a stent |
US20060020325A1 (en) * | 2004-07-26 | 2006-01-26 | Robert Burgermeister | Material for high strength, controlled recoil stent |
US20060134211A1 (en) * | 2004-12-16 | 2006-06-22 | Miv Therapeutics Inc. | Multi-layer drug delivery device and method of manufacturing same |
US20060136041A1 (en) * | 2004-12-17 | 2006-06-22 | Schmid Eric V | Slide-and-lock stent |
Non-Patent Citations (3)
Title |
---|
"Handbook of Pharmaceutical Additives: An International Guide to More Than 6000 Products by Trade Name, Chemical, Function, and Manufacturer", 1995, GOWER PUBLISHING LTD. |
J INTERV CARDIOL, vol. 17, no. 6, December 2004 (2004-12-01), pages 391 - 5 |
MARIO C.D. ET AL.: "Drug-Eluting Bioabsorbable Magnesium Stent", JOURNAL OF INTERVENTIONAL CARDIOLOGY, vol. 16, no. 6, December 2004 (2004-12-01), pages 391 - 395, XP008114932 * |
Cited By (49)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9827117B2 (en) | 2005-07-15 | 2017-11-28 | Micell Technologies, Inc. | Polymer coatings containing drug powder of controlled morphology |
US11911301B2 (en) | 2005-07-15 | 2024-02-27 | Micell Medtech Inc. | Polymer coatings containing drug powder of controlled morphology |
US10835396B2 (en) | 2005-07-15 | 2020-11-17 | Micell Technologies, Inc. | Stent with polymer coating containing amorphous rapamycin |
US8758429B2 (en) | 2005-07-15 | 2014-06-24 | Micell Technologies, Inc. | Polymer coatings containing drug powder of controlled morphology |
US10898353B2 (en) | 2005-07-15 | 2021-01-26 | Micell Technologies, Inc. | Polymer coatings containing drug powder of controlled morphology |
US8852625B2 (en) | 2006-04-26 | 2014-10-07 | Micell Technologies, Inc. | Coatings containing multiple drugs |
US9737645B2 (en) | 2006-04-26 | 2017-08-22 | Micell Technologies, Inc. | Coatings containing multiple drugs |
US9415142B2 (en) | 2006-04-26 | 2016-08-16 | Micell Technologies, Inc. | Coatings containing multiple drugs |
US11007307B2 (en) | 2006-04-26 | 2021-05-18 | Micell Technologies, Inc. | Coatings containing multiple drugs |
US11850333B2 (en) | 2006-04-26 | 2023-12-26 | Micell Medtech Inc. | Coatings containing multiple drugs |
US9539593B2 (en) | 2006-10-23 | 2017-01-10 | Micell Technologies, Inc. | Holder for electrically charging a substrate during coating |
US10617795B2 (en) | 2007-01-08 | 2020-04-14 | Micell Technologies, Inc. | Stents having biodegradable layers |
US9737642B2 (en) | 2007-01-08 | 2017-08-22 | Micell Technologies, Inc. | Stents having biodegradable layers |
US11426494B2 (en) | 2007-01-08 | 2022-08-30 | MT Acquisition Holdings LLC | Stents having biodegradable layers |
US9486338B2 (en) | 2007-04-17 | 2016-11-08 | Micell Technologies, Inc. | Stents having controlled elution |
US9433516B2 (en) | 2007-04-17 | 2016-09-06 | Micell Technologies, Inc. | Stents having controlled elution |
US9775729B2 (en) | 2007-04-17 | 2017-10-03 | Micell Technologies, Inc. | Stents having controlled elution |
US8900651B2 (en) | 2007-05-25 | 2014-12-02 | Micell Technologies, Inc. | Polymer films for medical device coating |
US10350333B2 (en) | 2008-04-17 | 2019-07-16 | Micell Technologies, Inc. | Stents having bioabsorable layers |
US9789233B2 (en) | 2008-04-17 | 2017-10-17 | Micell Technologies, Inc. | Stents having bioabsorbable layers |
US9510856B2 (en) | 2008-07-17 | 2016-12-06 | Micell Technologies, Inc. | Drug delivery medical device |
US9486431B2 (en) | 2008-07-17 | 2016-11-08 | Micell Technologies, Inc. | Drug delivery medical device |
US9981071B2 (en) | 2008-07-17 | 2018-05-29 | Micell Technologies, Inc. | Drug delivery medical device |
US10350391B2 (en) | 2008-07-17 | 2019-07-16 | Micell Technologies, Inc. | Drug delivery medical device |
US8834913B2 (en) | 2008-12-26 | 2014-09-16 | Battelle Memorial Institute | Medical implants and methods of making medical implants |
US10653820B2 (en) | 2009-04-01 | 2020-05-19 | Micell Technologies, Inc. | Coated stents |
US9981072B2 (en) | 2009-04-01 | 2018-05-29 | Micell Technologies, Inc. | Coated stents |
US11369498B2 (en) | 2010-02-02 | 2022-06-28 | MT Acquisition Holdings LLC | Stent and stent delivery system with improved deliverability |
US8795762B2 (en) | 2010-03-26 | 2014-08-05 | Battelle Memorial Institute | System and method for enhanced electrostatic deposition and surface coatings |
US9687864B2 (en) | 2010-03-26 | 2017-06-27 | Battelle Memorial Institute | System and method for enhanced electrostatic deposition and surface coatings |
WO2011130448A1 (fr) * | 2010-04-16 | 2011-10-20 | Micell Technologies, Inc. | Endoprothèses vasculaires ayant une élution contrôlée |
US10232092B2 (en) | 2010-04-22 | 2019-03-19 | Micell Technologies, Inc. | Stents and other devices having extracellular matrix coating |
US8377365B2 (en) | 2010-04-29 | 2013-02-19 | Medtronic Vascular, Inc. | System and method for stent manufacture |
WO2011136882A1 (fr) * | 2010-04-29 | 2011-11-03 | Medtronic Vascular Inc. | Système et procédé de fabrication d'une endoprothèse |
US11904118B2 (en) | 2010-07-16 | 2024-02-20 | Micell Medtech Inc. | Drug delivery medical device |
US9636309B2 (en) | 2010-09-09 | 2017-05-02 | Micell Technologies, Inc. | Macrolide dosage forms |
US10293050B2 (en) | 2010-09-09 | 2019-05-21 | Micell Technologies, Inc. | Macrolide dosage forms |
US10464100B2 (en) | 2011-05-31 | 2019-11-05 | Micell Technologies, Inc. | System and process for formation of a time-released, drug-eluting transferable coating |
US10729819B2 (en) | 2011-07-15 | 2020-08-04 | Micell Technologies, Inc. | Drug delivery medical device |
US10117972B2 (en) | 2011-07-15 | 2018-11-06 | Micell Technologies, Inc. | Drug delivery medical device |
US10188772B2 (en) | 2011-10-18 | 2019-01-29 | Micell Technologies, Inc. | Drug delivery medical device |
US11039943B2 (en) | 2013-03-12 | 2021-06-22 | Micell Technologies, Inc. | Bioabsorbable biomedical implants |
US10272606B2 (en) | 2013-05-15 | 2019-04-30 | Micell Technologies, Inc. | Bioabsorbable biomedical implants |
EP3868434A1 (fr) | 2016-02-08 | 2021-08-25 | Orbusneich Medical Pte. Ltd | Ballonnet à élution de médicament |
EP3868435A1 (fr) | 2016-02-08 | 2021-08-25 | Orbusneich Medical Pte. Ltd | Ballonnet à élution de médicament |
EP3871731A1 (fr) | 2016-02-08 | 2021-09-01 | Orbusneich Medical Pte. Ltd | Ballonnet à élution de médicament |
CN109803693A (zh) * | 2017-02-13 | 2019-05-24 | 先健科技(深圳)有限公司 | 医疗器械 |
CN115845152A (zh) * | 2017-02-13 | 2023-03-28 | 元心科技(深圳)有限公司 | 医疗器械 |
WO2018145528A1 (fr) * | 2017-02-13 | 2018-08-16 | 先健科技(深圳)有限公司 | Instrument médical |
Also Published As
Publication number | Publication date |
---|---|
EP2111184A1 (fr) | 2009-10-28 |
US9737642B2 (en) | 2017-08-22 |
EP2111184B1 (fr) | 2018-07-25 |
JP2010515539A (ja) | 2010-05-13 |
CA2679712A1 (fr) | 2008-07-17 |
US20100063580A1 (en) | 2010-03-11 |
JP2014012218A (ja) | 2014-01-23 |
US10617795B2 (en) | 2020-04-14 |
CA2679712C (fr) | 2016-11-15 |
JP5603598B2 (ja) | 2014-10-08 |
US20180000996A1 (en) | 2018-01-04 |
CN101711137A (zh) | 2010-05-19 |
EP2111184A4 (fr) | 2013-03-20 |
CN101711137B (zh) | 2014-10-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US10617795B2 (en) | Stents having biodegradable layers | |
US20230181802A1 (en) | Stents Having Biodegradable Layers | |
US20160271303A1 (en) | Stents having controlled elution | |
US11039943B2 (en) | Bioabsorbable biomedical implants | |
US8852625B2 (en) | Coatings containing multiple drugs | |
EP2531140B1 (fr) | Endoprothèse et système de pose d'endoprothèse avec une capacité améliorée de pose | |
WO2013177211A1 (fr) | Endoprothèse à élution de médicament sûre dotée d'un enrobage absorbable | |
US20190117851A1 (en) | Prolonged Drug-Eluting Products | |
AU2017200794B2 (en) | Stents having biodegradable layers | |
AU2012203577B2 (en) | Stents having biodegradable layers | |
US11426494B2 (en) | Stents having biodegradable layers | |
EP3862032A1 (fr) | Endoprothèses dotées de couches biodégradables | |
US20150134047A1 (en) | Safe drug eluting stent with absorbable coating |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 200880007308.1 Country of ref document: CN |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 08705772 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 2009545647 Country of ref document: JP Kind code of ref document: A |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 5060/DELNP/2009 Country of ref document: IN |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2008705772 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2679712 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 12522379 Country of ref document: US |